A Phase 2 interventional study of VLA15 and Placebo in Lyme Borreliosis, sponsored by Pfizer. Completed at 5 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.
Among the 54 studies in Lyme Disease with a site in United States, this one is the 9th largest by enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2019, is one of 6 in phase 2, and was the 26th registered.
98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.
Browse Lyme Disease studies →15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 7+ · Healthy volunteers
Columbia University · Sites in United States
Ages 18–70
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Children's National Research Institute · Sites in United States
Ages 18+ · Women only
Children's National Research Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 10
First in 1996; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 246 is above the median of 120 across 52 interventional studies indexed under Lyme Disease.
Median enrollment 72 across the 33 interventional studies, 410 across the 21 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 54 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Lyme Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Lyme Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500506Phase 3PfizerA Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | 2026-12-04 |
| NCT05776251Columbia UniversitytaVNS for Persistent Symptoms From Lyme Disease | 2026-11 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06511050Icahn School of Medicine at Mount SinaiLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2026-12 |
| NCT06397794Children's National Research InstituteNavigating Pregnancy and Parenthood With Lyme Disease | 2026-12-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 54 studies in Lyme Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the Main Study Phase a total of 246 subjects were randomized 2:2:1 into three treatment groups to receive either VLA15 with Alum (lower or higher dose) or Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1, Day 57 and Day 180.
In the Booster Phase subjects from the higher dose group who completed their primary immunization schedule according to protocol will be randomized 2:1 to receive an additional higher dose VLA15 vaccination or Placebo at Month 18.
Study duration in the Main Study Phase per subject is a maximum of 20 months. Overall study Duration is estimated to be 22 months.
Study duration per subject in the Booster Phase is a maximum of approximately 13 months.
Study duration per subject in the Main Study Phase and Booster Phase together is estimated to be a maximum of approximately 33 months.
Overall study duration (i.e., First-Subject-In to Last-Subject Out/ end of Booster Phase) is estimated to be approximately 37 months.
This is a randomized, observer-blind (subject, Sponsor and investigator/site staff involved in Clinical Evaluation of subjects are blinded), Placebo controlled, multicenter Phase 2 study.
In Main Study Phase a total of 246 healthy subjects,aged 18 to 65 years, were randomized 2:2:1 to receive either VLA15 with Alum (lower or higher doser Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1 (Month 0), Day 57 (Month 2) and Day 180 (Month 6).
Subjects from the higher dose group who completed their primary immunization schedule according to protocol, will be randomized 2:1 to receive an additional injection of the higher dose VLA15 with Alum or Placebo in a Booster Phase. The additional vaccination is administered as intramuscular injection approximately 18 months after the first immunization.
Inclusion Criteria - Main Study Phase:
Inclusion Criteria - Booster Phase:
If subject is of childbearing potential:
Exclusion Criteria - Main Study Phase:
Exclusion Criteria - Booster Phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Main Study Phase: VLA15 with Alum lower dose - Booster Phase: arm discontinued
Biological: VLA15
Main Study Phase: VLA15 with Alum higher dose - Booster Phase: VLA15 higher dose or placebo
Biological: VLA15
Main Study Phase: placebo - Booster Phase: arm discontinued
Biological: Placebo
a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
PBS (Phosphate Buffered Saline)
GMTs for IgG Against Each OspA Serotype
Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) against each Outer Surface Protein A (OspA) serotype ST1 to ST6, determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 208 (Month 7)
Time frame: Day 208 (Month 7)
GMTs for IgG Against Each OspA Serotype During the Main Study Phase
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 365 (Month 12) and 545 (Month 18).
Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 365 (Month 12) and Day 545 (Month 18)
SCRs for Each OspA Serotype Specific IgG During the Main Study Phase
Seroconversion Rate (SCR) for each Outer Surface Protein A (OspA) serotype specific IgG ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18). Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): greater than or equal to (\>=) 4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. Percentages are based on the number of participants with non-missing observations.
Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
GMFR as Compared to Baseline for IgG Against Each OspA Serotype During the Main Study Phase
Geometric Mean Fold Rise (GMFR) as compared to baseline for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18).
Time frame: Day 1 (baseline from where comparison was done), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
GMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years.
Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
GMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years.
Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
SCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years
SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants.
Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
SCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years
SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants.
Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
GMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years
GMFR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years.
Time frame: Day 1 (baseline), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
GMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years
GMFR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years.
Time frame: Day 1 (baseline), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18)
Percentage of Participants With Serious Adverse Events (SAEs) During the Main Study Phase
SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day 1 of vaccination up to Day 545 (Month 18)
Percentage of Participants With Related SAEs During the Main Study Phase
SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day 1 of vaccination up to Day 545 (Month 18)
Percentage of Participants Adverse Event of Special Interest (AESIs) During the Main Study Phase
AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day 1 of vaccination up to Day 545 (Month 18)
Percentage of Participants With Related AESIs During the Main Study Phase
AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day 1 of vaccination up to Day 545 (Month 18)
Percentage of Participants With Unsolicited AEs During the Main Study Phase
An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day 1 of vaccination up to Day 545 (Month 18)
Percentage of Participants With Related Unsolicited AEs During the Main Study Phase
An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day 1 of vaccination up to Day 545 (Month 18)
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Each and After Any Vaccination During the Main Study Phase
Solicited local AEs included pain, tenderness, induration (hardening), swelling and erythema (redness). Solicited systemic AEs included headache, myalgia (muscle pain), arthralgia (joint pain), fever (oral body temperature), flu-like symptoms, nausea, vomiting and fatigue. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: Up to 7 days after Vaccination 1, 2 and 3; Up to 7 days after any vaccination
Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Main Study Phase
Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs during main study phase stratified by age group 18-49 years and 50-65 years were reported. SAE: any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. AESI: any AEs of scientific/medical concern specific to study vaccine. Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AE: any untoward medical occurrence in participant associated with use of study vaccine, whether or not related to study vaccine, reported in addition to solicited and any solicited symptom with onset outside specified period of follow-up. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day 1 of vaccination up to Day 545 (Month 18)
GMTs for IgG Against Each OspA Serotype (ST1 to ST6): Booster Per-protocol (PP) Population
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
SCRs for Each OspA Serotype Specific IgG (ST1 to ST6): Booster PP Population
SCR for each OspA serotype specific IgG ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): greater than or equal to (\>=) 4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. Percentages are based on the number of participants with non-missing observations. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
GMFR as Compared to Baseline for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population
GMFR as compared to baseline for IgG against each Osp serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 were reported in this outcome measure. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
Time frame: Day 1 (baseline from where comparison was done), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
GMFR as Compared to Day 208 for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population
GMFR as compared to Day 208 for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Month 19, Month 24 and Month 30. The outcome measure was planned to be analyzed for Booster PP population from Day 208 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
Time frame: Day 208 (from where comparison was done), Month 19, Month 24 and Month 30
GMFR as Compared to Month 18 (Pre-booster) for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population
GMFR as compared to Month 18 (pre-booster) for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Month 19, Month 24 and Month 30. The outcome measure was planned to be analyzed for Booster PP population.
Time frame: Month 18 (from where comparison was done), Month 19, Month 24 and Month 30
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 18 - 49 years. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 50 - 65 years. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
Time frame: At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
SCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years
SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 18 - 49 years was presented in this outcome measure. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
SCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years
SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30 stratified by age group: 50 - 65 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
Time frame: Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30
Percentage of Participants With SAEs During the Entire Booster Phase
SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)
Percentage of Participants With Related SAEs During the Entire Booster Phase
SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)
Percentage of Participants With Adverse Event of Special Interest (AESIs) During the Entire Booster Phase
AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)
Percentage of Participants With Related AESIs During the Entire Booster Phase
AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months)
Percentage of Participants With Unsolicited AEs During the Booster Phase up to Month 19
An unsolicited AE includes any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month)
Percentage of Participants With Related Unsolicited AEs During the Booster Phase up to Month 19
An unsolicited AE included any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month)
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Booster Vaccination
Solicited local AEs included pain, tenderness, induration (hardening), swelling and erythema (redness). Solicited systemic AEs included headache, myalgia (muscle pain), arthralgia (joint pain), fever (oral body temperature), flu-like symptoms, nausea, vomiting and fatigue. Two-sided 95% confidence intervals were calculated according to Altman method.
Time frame: Within 7 days after booster vaccination
Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Booster Phase
Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs during booster phase stratified by age group 18-49 years and 50-65 years were reported. SAE: any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. AESI: any AEs of scientific/medical concern specific to study vaccine; Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AE: any untoward medical occurrence in participant associated with use of study vaccine, whether or not related to study vaccine, reported in addition to solicited and any solicited symptom with onset outside specified period of follow-up.
Time frame: SAEs and AESIs: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months); AEs: From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month)
| Milestone | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|---|---|---|
| Started | 97 | 98 | 51 | 0 | 0 |
| Completed | 89 | 84 | 46 | 0 | 0 |
| Not completed | 8 | 14 | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 7 | 2 | 0 | 0 |
| Withdrew: Moved from study area | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 5 | 3 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 | 0 |
| Milestone | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 39 | 19 |
| Completed | 0 | 0 | 0 | 39 | 18 |
| Not completed | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) against each Outer Surface Protein A (OspA) serotype ST1 to ST6, determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 208 (Month 7)
| Units per milliliter (U/mL) | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 208 | 278.5 (214.9 to 361.0) | 274.7 (209.4 to 360.4) | 21.0 (19.6 to 22.5) |
| ST2 Day 208 | 545.2 (431.8 to 688.4) | 579.8 (461.9 to 727.8) | 20.0 (20.0 to 20.0) |
| ST3 Day 208 | 520.0 (410.5 to 658.7) | 596.8 (471.9 to 754.8) | 20.0 (20.0 to 20.0) |
| ST4 Day 208 | 332.6 (261.3 to 423.3) | 367.8 (293.8 to 460.4) | 21.3 (19.8 to 23.0) |
| ST5 Day 208 | 332.8 (262.9 to 421.3) | 358.8 (283.7 to 453.7) | 20.0 (20.0 to 20.0) |
| ST6 Day 208 | 339.9 (267.3 to 432.3) | 345.7 (273.7 to 436.6) | 21.4 (19.4 to 23.5) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 365 (Month 12) and 545 (Month 18).
| Units per milliliter (U/mL) | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 1 | 21.4 (19.8 to 23.1) | 20.2 (19.8 to 20.6) | 21.8 (19.6 to 24.1) |
| ST1 Day 29 | 22.0 (20.2 to 24.0) | 20.4 (19.8 to 21.0) | 22.1 (19.9 to 24.6) |
| ST1 Day 57 | 22.5 (20.6 to 24.6) | 21.1 (19.9 to 22.3) | 21.6 (19.6 to 23.9) |
| ST1 Day 85 | 64.5 (50.7 to 82.0) | 75.2 (59.6 to 94.9) | 21.7 (19.7 to 23.8) |
| ST1 Day 180 | 26.4 (23.0 to 30.2) | 24.9 (22.7 to 27.4) | 21.5 (19.7 to 23.4) |
| ST1 Day 365 | 48.3 (39.1 to 59.7) | 37.2 (30.6 to 45.2) | 21.4 (19.8 to 23.1) |
| ST1 Day 545 | 29.7 (24.4 to 36.3) | 23.9 (21.5 to 26.7) | 20.6 (19.4 to 21.9) |
| ST2 Day 1 | 20.8 (19.9 to 21.8) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 29 | 21.5 (20.2 to 23.0) | 21.9 (20.2 to 23.6) | 20.0 (20.0 to 20.0) |
| ST2 Day 57 | 21.3 (20.0 to 22.6) | 22.0 (20.1 to 24.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 85 | 162.6 (127.0 to 208.2) | 183.5 (144.9 to 232.4) | 20.0 (20.0 to 20.0) |
| ST2 Day 180 | 38.0 (30.9 to 46.5) | 35.4 (29.9 to 41.9) | 20.0 (20.0 to 20.0) |
| ST2 Day 365 | 87.2 (69.0 to 110.2) | 71.1 (57.0 to 88.8) | 20.0 (20.0 to 20.0) |
| ST2 Day 545 | 44.6 (35.9 to 55.4) | 33.1 (27.5 to 39.7) | 21.1 (19.0 to 23.4) |
| ST3 Day 1 | 20.3 (19.8 to 20.8) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 29 | 21.3 (20.0 to 22.7) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 57 | 20.9 (19.8 to 22.1) | 20.7 (19.3 to 22.3) | 20.0 (20.0 to 20.0) |
| ST3 Day 85 | 166.3 (128.6 to 215.0) | 217.7 (171.7 to 275.9) | 20.7 (19.3 to 22.2) |
| ST3 Day 180 | 38.2 (31.6 to 46.1) | 41.0 (34.7 to 48.5) | 20.4 (19.6 to 21.4) |
| ST3 Day 365 | 78.5 (62.7 to 98.3) | 74.6 (59.6 to 93.3) | 20.0 (20.0 to 20.0) |
| ST3 Day 545 | 39.1 (31.9 to 48.0) | 32.2 (27.4 to 37.8) | 20.0 (20.0 to 20.0) |
| ST4 Day 1 | 20.7 (19.7 to 21.7) | 20.3 (19.7 to 21.0) | 20.5 (19.5 to 21.7) |
| ST4 Day 29 | 20.8 (19.7 to 21.9) | 20.5 (19.8 to 21.3) | 20.8 (19.7 to 22.0) |
| ST4 Day 57 | 21.0 (20.0 to 22.1) | 20.9 (19.8 to 22.1) | 21.2 (19.8 to 22.8) |
| ST4 Day 85 | 79.3 (63.2 to 99.6) | 100.8 (81.2 to 125.0) | 21.6 (20.0 to 23.3) |
| ST4 Day 180 | 28.0 (24.6 to 31.9) | 27.1 (24.1 to 30.4) | 21.3 (19.8 to 22.8) |
| ST4 Day 365 | 53.9 (44.1 to 65.9) | 43.2 (35.5 to 52.5) | 21.0 (19.6 to 22.5) |
| ST4 Day 545 | 35.5 (29.7 to 42.5) | 27.3 (24.0 to 31.1) | 22.4 (19.3 to 26.1) |
| ST5 Day 1 | 21.0 (19.9 to 22.2) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST5 Day 29 | 21.5 (20.0 to 23.1) | 20.9 (19.8 to 22.0) | 20.0 (20.0 to 20.0) |
| ST5 Day 57 | 21.3 (20.0 to 22.7) | 21.3 (19.9 to 22.9) | 20.0 (20.0 to 20.0) |
| ST5 Day 85 | 87.4 (69.1 to 110.5) | 100.2 (81.0 to 124.1) | 20.0 (20.0 to 20.0) |
| ST5 Day 180 | 29.0 (24.9 to 33.8) | 27.0 (24.1 to 30.3) | 20.0 (20.0 to 20.0) |
| ST5 Day 365 | 53.9 (43.5 to 66.9) | 42.7 (34.9 to 52.2) | 20.0 (20.0 to 20.0) |
| ST5 Day 545 | 35.0 (28.9 to 42.4) | 27.1 (23.8 to 30.9) | 20.4 (19.6 to 21.2) |
| ST6 Day 1 | 22.6 (20.6 to 24.8) | 20.7 (19.7 to 21.6) | 21.2 (19.5 to 23.1) |
| ST6 Day 29 | 23.3 (20.9 to 25.9) | 21.2 (20.0 to 22.4) | 21.0 (19.6 to 22.5) |
| ST6 Day 57 | 23.2 (21.0 to 25.6) | 22.2 (20.5 to 24.2) | 21.6 (19.8 to 23.6) |
| ST6 Day 85 | 79.9 (62.9 to 101.5) | 84.3 (67.4 to 105.4) | 20.7 (19.3 to 22.1) |
| ST6 Day 180 | 32.7 (27.8 to 38.4) | 28.8 (25.3 to 32.7) | 21.7 (19.7 to 23.9) |
| ST6 Day 365 | 61.1 (48.9 to 76.3) | 46.7 (37.9 to 57.5) | 21.5 (19.8 to 23.4) |
| ST6 Day 545 | 36.8 (30.0 to 45.3) | 27.1 (23.6 to 31.1) | 20.7 (19.3 to 22.1) |
Seroconversion Rate (SCR) for each Outer Surface Protein A (OspA) serotype specific IgG ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18). Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): greater than or equal to (\>=) 4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. Percentages are based on the number of participants with non-missing observations.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 29 | 2.4 (0.7 to 8.4) | 1.2 (0.2 to 6.3) | 2.3 (0.4 to 12.1) |
| ST1 Day 57 | 4.7 (1.8 to 11.5) | 3.5 (1.2 to 9.8) | 0.0 (0.0 to 8.2) |
| ST1 Day 85 | 59.0 (48.3 to 69.0) | 69.0 (58.5 to 77.9) | 2.3 (0.4 to 12.1) |
| ST1 Day 180 | 14.1 (8.3 to 23.1) | 19.8 (12.7 to 29.4) | 4.7 (1.3 to 15.5) |
| ST1 Day 208 | 92.3 (84.2 to 96.4) | 93.8 (86.2 to 97.3) | 0.0 (0.0 to 9.2) |
| ST1 Day 365 | 50.0 (39.4 to 60.6) | 38.0 (28.1 to 49.0) | 2.4 (0.4 to 12.3) |
| ST1 Day 545 | 17.8 (10.7 to 28.1) | 13.8 (7.5 to 24.3) | 0.0 (0.0 to 9.2) |
| ST2 Day 29 | 2.4 (0.7 to 8.4) | 5.8 (2.5 to 12.9) | 0.0 (0.0 to 8.2) |
| ST2 Day 57 | 1.2 (0.2 to 6.4) | 5.8 (2.5 to 12.9) | 0.0 (0.0 to 8.2) |
| ST2 Day 85 | 84.3 (75.0 to 90.6) | 89.3 (80.9 to 94.3) | 0.0 (0.0 to 8.2) |
| ST2 Day 180 | 32.9 (23.9 to 43.5) | 38.4 (28.8 to 48.9) | 0.0 (0.0 to 8.2) |
| ST2 Day 208 | 96.2 (89.3 to 98.7) | 98.8 (93.3 to 99.8) | 0.0 (0.0 to 9.2) |
| ST2 Day 365 | 72.0 (61.4 to 80.5) | 70.9 (60.1 to 79.7) | 0.0 (0.0 to 8.4) |
| ST2 Day 545 | 45.2 (34.3 to 56.6) | 35.4 (24.9 to 47.5) | 2.6 (0.5 to 13.5) |
| ST3 Day 29 | 3.6 (1.2 to 10.1) | 0.0 (0.0 to 4.3) | 0.0 (0.0 to 8.2) |
| ST3 Day 57 | 2.4 (0.6 to 8.2) | 1.2 (0.2 to 6.3) | 0.0 (0.0 to 8.2) |
| ST3 Day 85 | 84.3 (75.0 to 90.6) | 91.7 (83.8 to 95.9) | 2.3 (0.4 to 12.1) |
| ST3 Day 180 | 40.0 (30.2 to 50.6) | 50.0 (39.7 to 60.3) | 2.3 (0.4 to 12.1) |
| ST3 Day 208 | 98.7 (93.1 to 99.8) | 97.5 (91.3 to 99.3) | 0.0 (0.0 to 9.2) |
| ST3 Day 365 | 70.7 (60.1 to 79.5) | 70.9 (60.1 to 79.7) | 0.0 (0.0 to 8.4) |
| ST3 Day 545 | 42.5 (31.8 to 53.9) | 36.9 (26.2 to 49.1) | 0.0 (0.0 to 9.2) |
| ST4 Day 29 | 1.2 (0.2 to 6.5) | 1.2 (0.2 to 6.3) | 2.3 (0.4 to 12.1) |
| ST4 Day 57 | 2.4 (0.6 to 8.2) | 2.3 (0.6 to 8.1) | 4.7 (1.3 to 15.5) |
| ST4 Day 85 | 74.7 (64.4 to 82.8) | 83.3 (73.9 to 89.8) | 7.0 (2.4 to 18.6) |
| ST4 Day 180 | 25.9 (17.8 to 36.1) | 24.4 (16.6 to 34.5) | 4.7 (1.3 to 15.5) |
| ST4 Day 208 | 97.4 (91.1 to 99.3) | 98.8 (93.3 to 99.8) | 5.3 (1.5 to 17.3) |
| ST4 Day 365 | 62.2 (51.4 to 71.9) | 51.9 (41.1 to 62.6) | 2.4 (0.4 to 12.3) |
| ST4 Day 545 | 39.7 (29.3 to 51.2) | 27.7 (18.3 to 39.6) | 5.3 (1.5 to 17.3) |
| ST5 Day 29 | 1.2 (0.2 to 6.5) | 3.5 (1.2 to 9.8) | 0.0 (0.0 to 8.2) |
| ST5 Day 57 | 1.2 (0.2 to 6.4) | 4.7 (1.8 to 11.4) | 0.0 (0.0 to 8.2) |
| ST5 Day 85 | 73.5 (63.1 to 81.8) | 81.0 (71.3 to 87.9) | 0.0 (0.0 to 8.2) |
| ST5 Day 180 | 20.0 (12.9 to 29.7) | 25.6 (17.5 to 35.7) | 0.0 (0.0 to 8.2) |
| ST5 Day 208 | 94.9 (87.5 to 98.0) | 96.3 (89.5 to 98.7) | 0.0 (0.0 to 9.2) |
| ST5 Day 365 | 53.7 (42.9 to 64.0) | 48.1 (37.4 to 58.9) | 0.0 (0.0 to 8.4) |
| ST5 Day 545 | 34.2 (24.4 to 45.7) | 27.7 (18.3 to 39.6) | 2.6 (0.5 to 13.5) |
| ST6 Day 29 | 2.4 (0.7 to 8.4) | 2.3 (0.6 to 8.1) | 2.3 (0.4 to 12.1) |
| ST6 Day 57 | 3.5 (1.2 to 9.9) | 5.8 (2.5 to 12.9) | 4.7 (1.3 to 15.5) |
| ST6 Day 85 | 61.4 (50.7 to 71.2) | 71.4 (61.0 to 80.0) | 0.0 (0.0 to 8.2) |
| ST6 Day 180 | 27.1 (18.8 to 37.3) | 26.7 (18.5 to 36.9) | 4.7 (1.3 to 15.5) |
| ST6 Day 208 | 89.7 (81.0 to 94.7) | 96.3 (89.5 to 98.7) | 2.6 (0.5 to 13.5) |
| ST6 Day 365 | 56.1 (45.3 to 66.3) | 49.4 (38.6 to 60.2) | 4.8 (1.3 to 15.8) |
| ST6 Day 545 | 31.5 (22.0 to 42.9) | 21.5 (13.3 to 33.0) | 0.0 (0.0 to 9.2) |
Geometric Mean Fold Rise (GMFR) as compared to baseline for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18).
| Fold Rise | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.1) |
| ST1 Day 57 | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST1 Day 85 | 3.0 (2.4 to 3.8) | 3.7 (3.0 to 4.7) | 1.0 (0.9 to 1.1) |
| ST1 Day 180 | 1.2 (1.1 to 1.4) | 1.2 (1.1 to 1.4) | 1.0 (0.9 to 1.1) |
| ST1 Day 208 | 12.9 (9.8 to 17.1) | 13.6 (10.4 to 17.8) | 1.0 (0.9 to 1.0) |
| ST1 Day 365 | 2.3 (1.8 to 2.8) | 1.8 (1.5 to 2.2) | 1.0 (0.9 to 1.1) |
| ST1 Day 545 | 1.4 (1.1 to 1.7) | 1.2 (1.1 to 1.3) | 0.9 (0.9 to 1.0) |
| ST2 Day 29 | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.0) |
| ST2 Day 57 | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.0) |
| ST2 Day 85 | 7.8 (6.1 to 10.0) | 9.2 (7.2 to 11.6) | 1.0 (1.0 to 1.0) |
| ST2 Day 180 | 1.8 (1.5 to 2.2) | 1.8 (1.5 to 2.1) | 1.0 (1.0 to 1.0) |
| ST2 Day 208 | 26.1 (20.4 to 33.3) | 29.0 (23.1 to 36.4) | 1.0 (1.0 to 1.0) |
| ST2 Day 365 | 4.2 (3.3 to 5.3) | 3.6 (2.8 to 4.4) | 1.0 (1.0 to 1.0) |
| ST2 Day 545 | 2.1 (1.7 to 2.6) | 1.7 (1.4 to 2.0) | 1.1 (0.9 to 1.2) |
| ST3 Day 29 | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST3 Day 57 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST3 Day 85 | 8.2 (6.3 to 10.6) | 10.9 (8.6 to 13.8) | 1.0 (1.0 to 1.1) |
| ST3 Day 180 | 1.9 (1.6 to 2.3) | 2.1 (1.7 to 2.4) | 1.0 (1.0 to 1.1) |
| ST3 Day 208 | 25.6 (20.2 to 32.6) | 29.8 (23.6 to 37.7) | 1.0 (1.0 to 1.0) |
| ST3 Day 365 | 3.9 (3.1 to 4.9) | 3.7 (3.0 to 4.7) | 1.0 (1.0 to 1.0) |
| ST3 Day 545 | 2.0 (1.6 to 2.4) | 1.6 (1.4 to 1.9) | 1.0 (1.0 to 1.0) |
| ST4 Day 29 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST4 Day 57 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) |
| ST4 Day 85 | 3.8 (3.1 to 4.8) | 5.0 (4.0 to 6.1) | 1.1 (1.0 to 1.1) |
| ST4 Day 180 | 1.4 (1.2 to 1.5) | 1.3 (1.2 to 1.5) | 1.0 (1.0 to 1.1) |
| ST4 Day 208 | 16.0 (12.6 to 20.4) | 18.1 (14.5 to 22.6) | 1.0 (1.0 to 1.1) |
| ST4 Day 365 | 2.6 (2.1 to 3.2) | 2.1 (1.8 to 2.6) | 1.0 (1.0 to 1.1) |
| ST4 Day 545 | 1.7 (1.4 to 2.0) | 1.3 (1.2 to 1.5) | 1.1 (0.9 to 1.3) |
| ST5 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST5 Day 57 | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST5 Day 85 | 4.2 (3.3 to 5.2) | 5.0 (4.0 to 6.2) | 1.0 (1.0 to 1.0) |
| ST5 Day 180 | 1.4 (1.2 to 1.6) | 1.3 (1.2 to 1.5) | 1.0 (1.0 to 1.0) |
| ST5 Day 208 | 15.8 (12.4 to 20.0) | 17.9 (14.2 to 22.7) | 1.0 (1.0 to 1.0) |
| ST5 Day 365 | 2.6 (2.1 to 3.2) | 2.1 (1.7 to 2.6) | 1.0 (1.0 to 1.0) |
| ST5 Day 545 | 1.7 (1.4 to 2.0) | 1.4 (1.2 to 1.5) | 1.0 (1.0 to 1.1) |
| ST6 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (0.9 to 1.1) |
| ST6 Day 57 | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.2) | 1.0 (0.9 to 1.1) |
| ST6 Day 85 | 3.5 (2.8 to 4.5) | 4.1 (3.3 to 5.1) | 1.0 (0.9 to 1.0) |
| ST6 Day 180 | 1.4 (1.2 to 1.7) | 1.4 (1.2 to 1.6) | 1.0 (0.9 to 1.1) |
| ST6 Day 208 | 14.9 (11.4 to 19.3) | 16.7 (13.2 to 21.1) | 1.0 (0.9 to 1.1) |
| ST6 Day 365 | 2.7 (2.1 to 3.4) | 2.3 (1.8 to 2.8) | 1.0 (0.9 to 1.1) |
| ST6 Day 545 | 1.6 (1.3 to 1.9) | 1.3 (1.1 to 1.5) | 1.0 (0.9 to 1.0) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years.
| Units per milliliter (U/mL) | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 1 | 20.8 (19.3 to 22.4) | 20.3 (19.7 to 20.9) | 21.2 (19.5 to 23.1) |
| ST1 Day 29 | 21.3 (19.5 to 23.4) | 20.6 (19.8 to 21.5) | 21.2 (19.5 to 23.1) |
| ST1 Day 57 | 22.0 (19.9 to 24.3) | 20.9 (19.9 to 22.0) | 21.0 (19.6 to 22.5) |
| ST1 Day 85 | 60.8 (43.6 to 84.8) | 83.6 (61.7 to 113.2) | 21.3 (19.5 to 23.2) |
| ST1 Day 180 | 27.2 (22.7 to 32.5) | 25.1 (22.2 to 28.4) | 21.0 (19.6 to 22.6) |
| ST1 Day 208 | 284.1 (203.4 to 396.9) | 291.2 (211.6 to 400.8) | 20.6 (19.4 to 21.9) |
| ST1 Day 365 | 47.8 (36.4 to 62.7) | 37.4 (29.7 to 47.1) | 21.2 (19.5 to 23.1) |
| ST1 Day 545 | 30.9 (23.3 to 41.0) | 23.5 (20.6 to 26.6) | 20.0 (20.0 to 20.0) |
| ST2 Day 1 | 20.4 (19.6 to 21.3) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 29 | 21.5 (19.8 to 23.3) | 21.7 (19.8 to 23.9) | 20.0 (20.0 to 20.0) |
| ST2 Day 57 | 20.9 (19.6 to 22.3) | 22.5 (19.9 to 25.4) | 20.0 (20.0 to 20.0) |
| ST2 Day 85 | 155.9 (113.0 to 215.0) | 195.1 (145.0 to 262.6) | 20.0 (20.0 to 20.0) |
| ST2 Day 180 | 36.6 (28.9 to 46.4) | 36.0 (29.2 to 44.3) | 20.0 (20.0 to 20.0) |
| ST2 Day 208 | 551.9 (419.0 to 727.0) | 581.3 (465.3 to 726.2) | 20.0 (20.0 to 20.0) |
| ST2 Day 365 | 82.6 (62.2 to 109.7) | 66.1 (51.2 to 85.5) | 20.0 (20.0 to 20.0) |
| ST2 Day 545 | 46.3 (35.3 to 60.8) | 32.3 (26.1 to 39.8) | 21.6 (18.5 to 25.2) |
| ST3 Day 1 | 20.4 (19.6 to 21.2) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 29 | 21.7 (19.7 to 23.8) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 57 | 21.1 (19.5 to 22.8) | 21.1 (18.9 to 23.6) | 20.0 (20.0 to 20.0) |
| ST3 Day 85 | 178.3 (127.9 to 248.5) | 233.5 (172.9 to 315.2) | 21.0 (19.0 to 23.3) |
| ST3 Day 180 | 40.3 (31.4 to 51.8) | 42.6 (34.5 to 52.6) | 20.6 (19.3 to 22.0) |
| ST3 Day 208 | 573.5 (434.9 to 756.2) | 633.4 (507.5 to 790.6) | 20.0 (20.0 to 20.0) |
| ST3 Day 365 | 80.2 (60.2 to 106.8) | 71.3 (54.7 to 92.9) | 20.0 (20.0 to 20.0) |
| ST3 Day 545 | 40.8 (30.8 to 54.0) | 33.5 (27.1 to 41.3) | 20.0 (20.0 to 20.0) |
| ST4 Day 1 | 21.0 (19.6 to 22.6) | 20.5 (19.5 to 21.5) | 20.8 (19.2 to 22.4) |
| ST4 Day 29 | 21.2 (19.5 to 23.0) | 20.8 (19.7 to 21.9) | 20.7 (19.3 to 22.1) |
| ST4 Day 57 | 21.3 (19.8 to 23.0) | 21.4 (19.7 to 23.2) | 21.8 (19.7 to 24.1) |
| ST4 Day 85 | 84.4 (62.1 to 114.5) | 111.9 (85.1 to 147.2) | 21.7 (19.8 to 23.9) |
| ST4 Day 180 | 29.3 (24.5 to 35.2) | 27.7 (23.8 to 32.2) | 21.8 (19.7 to 24.1) |
| ST4 Day 208 | 365.2 (275.1 to 484.8) | 393.3 (311.9 to 495.8) | 22.0 (19.7 to 24.5) |
| ST4 Day 365 | 55.4 (42.7 to 72.0) | 42.6 (33.9 to 53.4) | 21.5 (19.4 to 23.8) |
| ST4 Day 545 | 40.9 (31.8 to 52.6) | 28.0 (23.7 to 33.0) | 23.6 (18.9 to 29.5) |
| ST5 Day 1 | 21.1 (19.6 to 22.6) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST5 Day 29 | 21.9 (19.7 to 24.2) | 20.4 (19.6 to 21.1) | 20.0 (20.0 to 20.0) |
| ST5 Day 57 | 21.5 (19.7 to 23.4) | 21.3 (19.3 to 23.5) | 20.0 (20.0 to 20.0) |
| ST5 Day 85 | 91.0 (66.9 to 123.7) | 106.4 (81.0 to 139.6) | 20.0 (20.0 to 20.0) |
| ST5 Day 180 | 30.0 (24.6 to 36.6) | 27.1 (23.5 to 31.3) | 20.0 (20.0 to 20.0) |
| ST5 Day 208 | 358.8 (269.7 to 477.4) | 371.0 (287.6 to 478.4) | 20.0 (20.0 to 20.0) |
| ST5 Day 365 | 54.5 (40.9 to 72.5) | 42.0 (33.3 to 53.1) | 20.0 (20.0 to 20.0) |
| ST5 Day 545 | 37.7 (28.8 to 49.4) | 26.8 (22.8 to 31.6) | 20.6 (19.4 to 21.8) |
| ST6 Day 1 | 23.0 (20.2 to 26.3) | 20.6 (19.5 to 21.7) | 21.0 (19.0 to 23.3) |
| ST6 Day 29 | 24.1 (20.6 to 28.0) | 21.0 (19.6 to 22.5) | 20.9 (19.1 to 22.8) |
| ST6 Day 57 | 23.5 (20.5 to 26.9) | 22.5 (20.1 to 25.3) | 21.6 (19.4 to 24.0) |
| ST6 Day 85 | 86.8 (63.6 to 118.4) | 85.4 (64.0 to 114.1) | 21.0 (19.0 to 23.1) |
| ST6 Day 180 | 32.9 (26.5 to 40.8) | 27.5 (23.5 to 32.1) | 21.6 (19.3 to 24.3) |
| ST6 Day 208 | 362.4 (277.1 to 473.9) | 337.5 (258.2 to 441.1) | 21.2 (18.8 to 23.8) |
| ST6 Day 365 | 61.2 (45.9 to 81.8) | 41.7 (32.7 to 53.2) | 21.6 (19.3 to 24.1) |
| ST6 Day 545 | 41.1 (30.7 to 55.0) | 24.7 (21.2 to 28.9) | 21.0 (19.0 to 23.1) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years.
| Units per milliliter (U/mL) | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 1 | 22.6 (19.0 to 26.8) | 20.0 (20.0 to 20.0) | 23.1 (16.9 to 31.5) |
| ST1 Day 29 | 23.3 (19.6 to 27.8) | 20.0 (20.0 to 20.0) | 24.4 (17.7 to 33.8) |
| ST1 Day 57 | 23.5 (19.5 to 28.3) | 21.4 (18.6 to 24.6) | 23.2 (16.8 to 31.9) |
| ST1 Day 85 | 71.5 (51.2 to 100.0) | 61.6 (42.8 to 88.5) | 22.6 (17.3 to 29.6) |
| ST1 Day 180 | 24.9 (20.1 to 30.9) | 24.5 (20.9 to 28.6) | 22.5 (17.4 to 29.1) |
| ST1 Day 208 | 269.3 (174.1 to 416.5) | 246.6 (145.6 to 417.5) | 21.9 (18.0 to 26.6) |
| ST1 Day 365 | 49.2 (34.4 to 70.4) | 36.8 (25.3 to 53.4) | 21.8 (18.1 to 26.2) |
| ST1 Day 545 | 27.9 (21.4 to 36.5) | 24.8 (20.1 to 30.5) | 21.9 (17.9 to 26.9) |
| ST2 Day 1 | 21.6 (19.3 to 24.2) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 29 | 21.7 (19.3 to 24.4) | 22.1 (19.0 to 25.7) | 20.0 (20.0 to 20.0) |
| ST2 Day 57 | 21.9 (19.2 to 25.0) | 21.1 (18.9 to 23.5) | 20.0 (20.0 to 20.0) |
| ST2 Day 85 | 175.3 (117.0 to 262.6) | 163.4 (108.4 to 246.1) | 20.0 (20.0 to 20.0) |
| ST2 Day 180 | 40.5 (27.2 to 60.4) | 34.3 (25.4 to 46.3) | 20.0 (20.0 to 20.0) |
| ST2 Day 208 | 534.1 (342.5 to 832.8) | 577.0 (340.7 to 977.2) | 20.0 (20.0 to 20.0) |
| ST2 Day 365 | 95.9 (62.4 to 147.5) | 80.6 (52.4 to 124.2) | 20.0 (20.0 to 20.0) |
| ST2 Day 545 | 41.9 (28.5 to 61.7) | 34.5 (23.9 to 49.7) | 20.0 (20.0 to 20.0) |
| ST3 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 29 | 20.6 (19.4 to 21.9) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 57 | 20.6 (19.4 to 21.8) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 85 | 147.1 (96.3 to 224.7) | 190.6 (127.1 to 285.7) | 20.0 (20.0 to 20.0) |
| ST3 Day 180 | 34.5 (25.8 to 46.2) | 38.1 (28.4 to 51.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 208 | 440.6 (281.3 to 690.1) | 534.3 (307.0 to 930.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 365 | 75.7 (51.5 to 111.2) | 80.6 (52.7 to 123.4) | 20.0 (20.0 to 20.0) |
| ST3 Day 545 | 36.6 (27.0 to 49.7) | 30.1 (23.1 to 39.1) | 20.0 (20.0 to 20.0) |
| ST4 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST4 Day 29 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) | 21.1 (18.8 to 23.7) |
| ST4 Day 57 | 20.5 (19.5 to 21.7) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST4 Day 85 | 71.1 (50.4 to 100.3) | 82.6 (57.9 to 117.7) | 21.3 (18.6 to 24.3) |
| ST4 Day 180 | 25.7 (21.8 to 30.3) | 25.9 (21.6 to 31.0) | 20.0 (20.0 to 20.0) |
| ST4 Day 208 | 283.9 (179.8 to 448.3) | 324.8 (197.4 to 534.3) | 20.0 (20.0 to 20.0) |
| ST4 Day 365 | 51.4 (37.0 to 71.4) | 44.3 (30.2 to 64.8) | 20.0 (20.0 to 20.0) |
| ST4 Day 545 | 28.3 (22.6 to 35.5) | 26.3 (21.2 to 32.7) | 20.0 (20.0 to 20.0) |
| ST5 Day 1 | 20.9 (19.1 to 22.8) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST5 Day 29 | 20.8 (19.2 to 22.7) | 21.9 (19.0 to 25.3) | 20.0 (20.0 to 20.0) |
| ST5 Day 57 | 20.9 (19.1 to 23.0) | 21.4 (19.4 to 23.7) | 20.0 (20.0 to 20.0) |
| ST5 Day 85 | 81.4 (55.9 to 118.5) | 89.6 (62.6 to 128.2) | 20.0 (20.0 to 20.0) |
| ST5 Day 180 | 27.3 (21.3 to 34.9) | 26.7 (21.8 to 32.8) | 20.0 (20.0 to 20.0) |
| ST5 Day 208 | 293.1 (190.5 to 451.0) | 337.2 (204.3 to 556.6) | 20.0 (20.0 to 20.0) |
| ST5 Day 365 | 52.9 (37.7 to 74.4) | 43.8 (29.7 to 64.6) | 20.0 (20.0 to 20.0) |
| ST5 Day 545 | 31.0 (23.9 to 40.3) | 27.6 (21.7 to 35.0) | 20.0 (20.0 to 20.0) |
| ST6 Day 1 | 21.8 (19.3 to 24.8) | 20.9 (19.1 to 22.8) | 21.7 (18.1 to 26.1) |
| ST6 Day 29 | 22.0 (19.2 to 25.1) | 21.5 (19.4 to 23.8) | 21.3 (18.6 to 24.3) |
| ST6 Day 57 | 22.7 (19.6 to 26.4) | 21.7 (19.3 to 24.3) | 21.7 (18.2 to 25.9) |
| ST6 Day 85 | 69.0 (46.8 to 101.9) | 82.1 (56.8 to 118.7) | 20.0 (20.0 to 20.0) |
| ST6 Day 180 | 32.3 (25.2 to 41.4) | 31.6 (25.0 to 39.9) | 21.9 (18.0 to 26.7) |
| ST6 Day 208 | 305.1 (188.3 to 494.3) | 361.4 (225.9 to 578.3) | 21.8 (18.0 to 26.4) |
| ST6 Day 365 | 60.7 (42.0 to 87.9) | 56.6 (38.3 to 83.7) | 21.4 (18.5 to 24.6) |
| ST6 Day 545 | 30.9 (23.5 to 40.8) | 31.6 (24.1 to 41.4) | 20.0 (20.0 to 20.0) |
SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 29 | 1.9 (0.3 to 9.9) | 1.8 (0.3 to 9.3) | 0.0 (0.0 to 11.4) |
| ST1 Day 57 | 5.5 (1.9 to 14.9) | 3.5 (1.0 to 11.9) | 0.0 (0.0 to 11.4) |
| ST1 Day 85 | 54.7 (41.5 to 67.3) | 70.9 (57.9 to 81.2) | 3.3 (0.6 to 16.7) |
| ST1 Day 180 | 18.2 (10.2 to 30.3) | 19.3 (11.1 to 31.3) | 6.7 (1.8 to 21.3) |
| ST1 Day 208 | 93.9 (83.5 to 97.9) | 94.2 (84.4 to 98.0) | 0.0 (0.0 to 12.9) |
| ST1 Day 365 | 51.9 (38.7 to 64.9) | 38.0 (25.9 to 51.8) | 3.4 (0.6 to 17.2) |
| ST1 Day 545 | 20.0 (10.9 to 33.8) | 12.2 (5.3 to 25.5) | 0.0 (0.0 to 12.9) |
| ST2 Day 29 | 3.8 (1.0 to 12.8) | 5.3 (1.8 to 14.4) | 0.0 (0.0 to 11.4) |
| ST2 Day 57 | 1.8 (0.3 to 9.6) | 7.0 (2.8 to 16.7) | 0.0 (0.0 to 11.4) |
| ST2 Day 85 | 84.9 (72.9 to 92.1) | 90.9 (80.4 to 96.1) | 0.0 (0.0 to 11.4) |
| ST2 Day 180 | 34.5 (23.4 to 47.7) | 38.6 (27.1 to 51.6) | 0.0 (0.0 to 11.4) |
| ST2 Day 208 | 100 (92.7 to 100) | 100 (93.1 to 100) | 0.0 (0.0 to 12.9) |
| ST2 Day 365 | 73.1 (59.7 to 83.2) | 70.0 (56.2 to 80.9) | 0.0 (0.0 to 11.7) |
| ST2 Day 545 | 53.3 (39.1 to 67.1) | 36.6 (23.6 to 51.9) | 3.8 (0.7 to 18.9) |
| ST3 Day 29 | 3.8 (1.0 to 12.8) | 0.0 (0.0 to 6.3) | 0.0 (0.0 to 11.4) |
| ST3 Day 57 | 1.8 (0.3 to 9.6) | 1.8 (0.3 to 9.3) | 0.0 (0.0 to 11.4) |
| ST3 Day 85 | 84.9 (72.9 to 92.1) | 92.7 (82.7 to 97.1) | 3.3 (0.6 to 16.7) |
| ST3 Day 180 | 41.8 (29.7 to 55.0) | 52.6 (39.9 to 65.0) | 3.3 (0.6 to 16.7) |
| ST3 Day 208 | 100 (92.7 to 100) | 100 (93.1 to 100) | 0.0 (0.0 to 12.9) |
| ST3 Day 365 | 69.2 (55.7 to 80.1) | 72.0 (58.3 to 82.5) | 0.0 (0.0 to 11.7) |
| ST3 Day 545 | 42.2 (29.0 to 56.7) | 39.0 (25.7 to 54.3) | 0.0 (0.0 to 12.9) |
| ST4 Day 29 | 1.9 (0.3 to 9.9) | 1.8 (0.3 to 9.3) | 0.0 (0.0 to 11.4) |
| ST4 Day 57 | 1.8 (0.3 to 9.6) | 3.5 (1.0 to 11.9) | 6.7 (1.8 to 21.3) |
| ST4 Day 85 | 75.5 (62.4 to 85.1) | 87.3 (76.0 to 93.7) | 6.7 (1.8 to 21.3) |
| ST4 Day 180 | 25.5 (15.8 to 38.3) | 24.6 (15.2 to 37.1) | 6.7 (1.8 to 21.3) |
| ST4 Day 208 | 100 (92.7 to 100) | 100 (93.1 to 100) | 7.7 (2.1 to 24.1) |
| ST4 Day 365 | 61.5 (48.0 to 73.5) | 52.0 (38.5 to 65.2) | 3.4 (0.6 to 17.2) |
| ST4 Day 545 | 46.7 (32.9 to 60.9) | 29.3 (17.6 to 44.5) | 7.7 (2.1 to 24.1) |
| ST5 Day 29 | 1.9 (0.3 to 9.9) | 1.8 (0.3 to 9.3) | 0.0 (0.0 to 11.4) |
| ST5 Day 57 | 1.8 (0.3 to 9.6) | 3.5 (1.0 to 11.9) | 0.0 (0.0 to 11.4) |
| ST5 Day 85 | 73.6 (60.4 to 83.6) | 81.8 (69.7 to 89.8) | 0.0 (0.0 to 11.4) |
| ST5 Day 180 | 21.8 (12.9 to 34.4) | 26.3 (16.6 to 39.0) | 0.0 (0.0 to 11.4) |
| ST5 Day 208 | 95.9 (86.3 to 98.9) | 98.1 (89.9 to 99.7) | 0.0 (0.0 to 12.9) |
| ST5 Day 365 | 51.9 (38.7 to 64.9) | 48.0 (34.8 to 61.5) | 0.0 (0.0 to 11.7) |
| ST5 Day 545 | 37.8 (25.1 to 52.4) | 26.8 (15.7 to 41.9) | 3.8 (0.7 to 18.9) |
| ST6 Day 29 | 3.8 (1.0 to 12.8) | 1.8 (0.3 to 9.3) | 0.0 (0.0 to 11.4) |
| ST6 Day 57 | 3.6 (1.0 to 12.3) | 7.0 (2.8 to 16.7) | 3.3 (0.6 to 16.7) |
| ST6 Day 85 | 62.3 (48.8 to 74.1) | 70.9 (57.9 to 81.2) | 0.0 (0.0 to 11.4) |
| ST6 Day 180 | 25.5 (15.8 to 38.3) | 22.8 (13.8 to 35.2) | 3.3 (0.6 to 16.7) |
| ST6 Day 208 | 89.8 (78.2 to 95.6) | 96.2 (87.0 to 98.9) | 0.0 (0.0 to 12.9) |
| ST6 Day 365 | 55.8 (42.3 to 68.4) | 44.0 (31.2 to 57.7) | 3.4 (0.6 to 17.2) |
| ST6 Day 545 | 37.8 (25.1 to 52.4) | 14.6 (6.9 to 28.4) | 0.0 (0.0 to 12.9) |
SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 29 | 3.3 (0.6 to 16.7) | 0.0 (0.0 to 11.7) | 7.7 (1.4 to 33.3) |
| ST1 Day 57 | 3.3 (0.6 to 16.7) | 3.4 (0.6 to 17.2) | 0.0 (0.0 to 22.8) |
| ST1 Day 85 | 66.7 (48.8 to 80.8) | 65.5 (47.3 to 80.1) | 0.0 (0.0 to 22.8) |
| ST1 Day 180 | 6.7 (1.8 to 21.3) | 20.7 (9.8 to 38.4) | 0.0 (0.0 to 22.8) |
| ST1 Day 208 | 89.7 (73.6 to 96.4) | 92.9 (77.4 to 98.0) | 0.0 (0.0 to 24.2) |
| ST1 Day 365 | 46.7 (30.2 to 63.9) | 37.9 (22.7 to 56.0) | 0.0 (0.0 to 22.8) |
| ST1 Day 545 | 14.3 (5.7 to 31.5) | 16.7 (6.7 to 35.9) | 0.0 (0.0 to 24.2) |
| ST2 Day 29 | 0.0 (0.0 to 11.4) | 6.9 (1.9 to 22.0) | 0.0 (0.0 to 22.8) |
| ST2 Day 57 | 0.0 (0.0 to 11.4) | 3.4 (0.6 to 17.2) | 0.0 (0.0 to 22.8) |
| ST2 Day 85 | 83.3 (66.4 to 92.7) | 86.2 (69.4 to 94.5) | 0.0 (0.0 to 22.8) |
| ST2 Day 180 | 30.0 (16.7 to 47.9) | 37.9 (22.7 to 56.0) | 0.0 (0.0 to 22.8) |
| ST2 Day 208 | 89.7 (73.6 to 96.4) | 96.4 (82.3 to 99.4) | 0.0 (0.0 to 24.2) |
| ST2 Day 365 | 70.0 (52.1 to 83.3) | 72.4 (54.3 to 85.3) | 0.0 (0.0 to 22.8) |
| ST2 Day 545 | 32.1 (17.9 to 50.7) | 33.3 (18.0 to 53.3) | 0.0 (0.0 to 24.2) |
| ST3 Day 29 | 3.3 (0.6 to 16.7) | 0.0 (0.0 to 11.7) | 0.0 (0.0 to 22.8) |
| ST3 Day 57 | 3.3 (0.6 to 16.7) | 0.0 (0.0 to 11.7) | 0.0 (0.0 to 22.8) |
| ST3 Day 85 | 83.3 (66.4 to 92.7) | 89.7 (73.6 to 96.4) | 0.0 (0.0 to 22.8) |
| ST3 Day 180 | 36.7 (21.9 to 54.5) | 44.8 (28.4 to 62.5) | 0.0 (0.0 to 22.8) |
| ST3 Day 208 | 96.6 (82.8 to 99.4) | 92.9 (77.4 to 98.0) | 0.0 (0.0 to 24.2) |
| ST3 Day 365 | 73.3 (55.6 to 85.8) | 69.0 (50.8 to 82.7) | 0.0 (0.0 to 22.8) |
| ST3 Day 545 | 42.9 (26.5 to 60.9) | 33.3 (18.0 to 53.3) | 0.0 (0.0 to 24.2) |
| ST4 Day 29 | 0.0 (0.0 to 11.4) | 0.0 (0.0 to 11.7) | 7.7 (1.4 to 33.3) |
| ST4 Day 57 | 3.3 (0.6 to 16.7) | 0.0 (0.0 to 11.7) | 0.0 (0.0 to 22.8) |
| ST4 Day 85 | 73.3 (55.6 to 85.8) | 75.9 (57.9 to 87.8) | 7.7 (1.4 to 33.3) |
| ST4 Day 180 | 26.7 (14.2 to 44.4) | 24.1 (12.2 to 42.1) | 0.0 (0.0 to 22.8) |
| ST4 Day 208 | 93.1 (78.0 to 98.1) | 96.4 (82.3 to 99.4) | 0.0 (0.0 to 24.2) |
| ST4 Day 365 | 63.3 (45.5 to 78.1) | 51.7 (34.4 to 68.6) | 0.0 (0.0 to 22.8) |
| ST4 Day 545 | 28.6 (15.3 to 47.1) | 25.0 (12.0 to 44.9) | 0.0 (0.0 to 24.2) |
| ST5 Day 29 | 0.0 (0.0 to 11.4) | 6.9 (1.9 to 22.0) | 0.0 (0.0 to 22.8) |
| ST5 Day 57 | 0.0 (0.0 to 11.4) | 6.9 (1.9 to 22.0) | 0.0 (0.0 to 22.8) |
| ST5 Day 85 | 73.3 (55.6 to 85.8) | 79.3 (61.6 to 90.2) | 0.0 (0.0 to 22.8) |
| ST5 Day 180 | 16.7 (7.3 to 33.6) | 24.1 (12.2 to 42.1) | 0.0 (0.0 to 22.8) |
| ST5 Day 208 | 93.1 (78.0 to 98.1) | 92.9 (77.4 to 98.0) | 0.0 (0.0 to 24.2) |
| ST5 Day 365 | 56.7 (39.2 to 72.6) | 48.3 (31.4 to 65.6) | 0.0 (0.0 to 22.8) |
| ST5 Day 545 | 28.6 (15.3 to 47.1) | 29.2 (14.9 to 49.2) | 0.0 (0.0 to 24.2) |
| ST6 Day 29 | 0.0 (0.0 to 11.4) | 3.4 (0.6 to 17.2) | 7.7 (1.4 to 33.3) |
| ST6 Day 57 | 3.3 (0.6 to 16.7) | 3.4 (0.6 to 17.2) | 7.7 (1.4 to 33.3) |
| ST6 Day 85 | 60.0 (42.3 to 75.4) | 72.4 (54.3 to 85.3) | 0.0 (0.0 to 22.8) |
| ST6 Day 180 | 30.0 (16.7 to 47.9) | 34.5 (19.9 to 52.7) | 7.7 (1.4 to 33.3) |
| ST6 Day 208 | 89.7 (73.6 to 96.4) | 96.4 (82.3 to 99.4) | 8.3 (1.5 to 35.4) |
| ST6 Day 365 | 56.7 (39.2 to 72.6) | 58.6 (40.7 to 74.5) | 7.7 (1.4 to 33.3) |
| ST6 Day 545 | 21.4 (10.2 to 39.5) | 33.3 (18.0 to 53.3) | 0.0 (0.0 to 24.2) |
GMFR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 18 - 49 years.
| Fold Rise | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST1 Day 57 | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST1 Day 85 | 2.9 (2.1 to 4.1) | 4.1 (3.0 to 5.6) | 1.0 (0.9 to 1.1) |
| ST1 Day 180 | 1.3 (1.1 to 1.6) | 1.2 (1.1 to 1.4) | 1.0 (0.9 to 1.1) |
| ST1 Day 208 | 13.6 (9.7 to 19.2) | 14.3 (10.4 to 19.7) | 1.0 (0.9 to 1.0) |
| ST1 Day 365 | 2.3 (1.8 to 3.0) | 1.8 (1.5 to 2.3) | 1.0 (0.9 to 1.1) |
| ST1 Day 545 | 1.5 (1.1 to 1.9) | 1.1 (1.0 to 1.3) | 0.9 (0.8 to 1.0) |
| ST2 Day 29 | 1.1 (1.0 to 1.1) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.0) |
| ST2 Day 57 | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.3) | 1.0 (1.0 to 1.0) |
| ST2 Day 85 | 7.6 (5.5 to 10.5) | 9.8 (7.2 to 13.1) | 1.0 (1.0 to 1.0) |
| ST2 Day 180 | 1.8 (1.4 to 2.3) | 1.8 (1.5 to 2.2) | 1.0 (1.0 to 1.0) |
| ST2 Day 208 | 27.0 (20.5 to 35.5) | 29.1 (23.3 to 36.3) | 1.0 (1.0 to 1.0) |
| ST2 Day 365 | 4.0 (3.0 to 5.4) | 3.3 (2.6 to 4.3) | 1.0 (1.0 to 1.0) |
| ST2 Day 545 | 2.3 (1.7 to 2.9) | 1.6 (1.3 to 2.0) | 1.1 (0.9 to 1.3) |
| ST3 Day 29 | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST3 Day 57 | 1.0 (1.0 to 1.1) | 1.1 (0.9 to 1.2) | 1.0 (1.0 to 1.0) |
| ST3 Day 85 | 8.7 (6.2 to 12.2) | 11.7 (8.6 to 15.8) | 1.1 (0.9 to 1.2) |
| ST3 Day 180 | 2.0 (1.5 to 2.5) | 2.1 (1.7 to 2.6) | 1.0 (1.0 to 1.1) |
| ST3 Day 208 | 28.1 (21.1 to 37.3) | 31.7 (25.4 to 39.5) | 1.0 (1.0 to 1.0) |
| ST3 Day 365 | 3.9 (2.9 to 5.2) | 3.6 (2.7 to 4.6) | 1.0 (1.0 to 1.0) |
| ST3 Day 545 | 2.0 (1.5 to 2.7) | 1.7 (1.4 to 2.1) | 1.0 (1.0 to 1.0) |
| ST4 Day 29 | 1.0 (0.9 to 1.1) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST4 Day 57 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) |
| ST4 Day 85 | 4.0 (3.0 to 5.4) | 5.5 (4.2 to 7.1) | 1.0 (1.0 to 1.1) |
| ST4 Day 180 | 1.4 (1.2 to 1.7) | 1.4 (1.2 to 1.6) | 1.1 (1.0 to 1.1) |
| ST4 Day 208 | 17.2 (13.0 to 22.9) | 19.1 (15.3 to 24.0) | 1.1 (1.0 to 1.1) |
| ST4 Day 365 | 2.6 (2.0 to 3.4) | 2.1 (1.7 to 2.6) | 1.0 (1.0 to 1.1) |
| ST4 Day 545 | 1.9 (1.5 to 2.5) | 1.4 (1.2 to 1.6) | 1.1 (0.9 to 1.4) |
| ST5 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST5 Day 57 | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.0) |
| ST5 Day 85 | 4.3 (3.2 to 5.8) | 5.3 (4.1 to 7.0) | 1.0 (1.0 to 1.0) |
| ST5 Day 180 | 1.4 (1.2 to 1.7) | 1.4 (1.2 to 1.6) | 1.0 (1.0 to 1.0) |
| ST5 Day 208 | 16.9 (12.6 to 22.8) | 18.5 (14.4 to 23.9) | 1.0 (1.0 to 1.0) |
| ST5 Day 365 | 2.6 (1.9 to 3.4) | 2.1 (1.7 to 2.7) | 1.0 (1.0 to 1.0) |
| ST5 Day 545 | 1.8 (1.4 to 2.3) | 1.3 (1.1 to 1.6) | 1.0 (1.0 to 1.1) |
| ST6 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST6 Day 57 | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.1) |
| ST6 Day 85 | 3.7 (2.7 to 5.1) | 4.2 (3.1 to 5.5) | 1.0 (1.0 to 1.0) |
| ST6 Day 180 | 1.4 (1.2 to 1.8) | 1.3 (1.2 to 1.5) | 1.0 (1.0 to 1.1) |
| ST6 Day 208 | 15.5 (11.1 to 21.4) | 16.4 (12.5 to 21.4) | 1.0 (1.0 to 1.0) |
| ST6 Day 365 | 2.6 (1.9 to 3.6) | 2.0 (1.6 to 2.5) | 1.0 (1.0 to 1.1) |
| ST6 Day 545 | 1.7 (1.3 to 2.3) | 1.2 (1.0 to 1.4) | 1.0 (1.0 to 1.0) |
GMFR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12) and 545 (Month 18) stratified by age group: 50 - 65 years.
| Fold Rise | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| ST1 Day 29 | 1.0 (0.9 to 1.1) | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.2) |
| ST1 Day 57 | 1.0 (0.9 to 1.1) | 1.1 (0.9 to 1.2) | 1.0 (1.0 to 1.0) |
| ST1 Day 85 | 3.2 (2.3 to 4.5) | 3.1 (2.1 to 4.4) | 1.0 (0.9 to 1.0) |
| ST1 Day 180 | 1.1 (1.0 to 1.3) | 1.2 (1.0 to 1.4) | 1.0 (0.9 to 1.0) |
| ST1 Day 208 | 11.9 (7.2 to 19.5) | 12.3 (7.3 to 20.9) | 0.9 (0.8 to 1.1) |
| ST1 Day 365 | 2.2 (1.5 to 3.1) | 1.8 (1.3 to 2.7) | 0.9 (0.8 to 1.1) |
| ST1 Day 545 | 1.2 (1.0 to 1.5) | 1.2 (1.0 to 1.5) | 0.9 (0.8 to 1.1) |
| ST2 Day 29 | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 1.3) | 1.0 (1.0 to 1.0) |
| ST2 Day 57 | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.2) | 1.0 (1.0 to 1.0) |
| ST2 Day 85 | 8.1 (5.3 to 12.5) | 8.2 (5.4 to 12.3) | 1.0 (1.0 to 1.0) |
| ST2 Day 180 | 1.9 (1.3 to 2.8) | 1.7 (1.3 to 2.3) | 1.0 (1.0 to 1.0) |
| ST2 Day 208 | 24.6 (15.1 to 40.0) | 28.8 (17.0 to 48.9) | 1.0 (1.0 to 1.0) |
| ST2 Day 365 | 4.4 (2.9 to 6.9) | 4.0 (2.6 to 6.2) | 1.0 (1.0 to 1.0) |
| ST2 Day 545 | 1.9 (1.3 to 2.8) | 1.7 (1.2 to 2.5) | 1.0 (1.0 to 1.0) |
| ST3 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST3 Day 57 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST3 Day 85 | 7.4 (4.8 to 11.2) | 9.5 (6.4 to 14.3) | 1.0 (1.0 to 1.0) |
| ST3 Day 180 | 1.7 (1.3 to 2.3) | 1.9 (1.4 to 2.6) | 1.0 (1.0 to 1.0) |
| ST3 Day 208 | 22.0 (14.1 to 34.5) | 26.7 (15.4 to 46.5) | 1.0 (1.0 to 1.0) |
| ST3 Day 365 | 3.8 (2.6 to 5.6) | 4.0 (2.6 to 6.2) | 1.0 (1.0 to 1.0) |
| ST3 Day 545 | 1.8 (1.4 to 2.5) | 1.5 (1.2 to 2.0) | 1.0 (1.0 to 1.0) |
| ST4 Day 29 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.2) |
| ST4 Day 57 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST4 Day 85 | 3.6 (2.5 to 5.0) | 4.1 (2.9 to 5.9) | 1.1 (0.9 to 1.2) |
| ST4 Day 180 | 1.3 (1.1 to 1.5) | 1.3 (1.1 to 1.5) | 1.0 (1.0 to 1.0) |
| ST4 Day 208 | 14.2 (9.0 to 22.4) | 16.2 (9.9 to 26.7) | 1.0 (1.0 to 1.0) |
| ST4 Day 365 | 2.6 (1.8 to 3.6) | 2.2 (1.5 to 3.2) | 1.0 (1.0 to 1.0) |
| ST4 Day 545 | 1.4 (1.1 to 1.8) | 1.3 (1.1 to 1.6) | 1.0 (1.0 to 1.0) |
| ST5 Day 29 | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.3) | 1.0 (1.0 to 1.0) |
| ST5 Day 57 | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.0) |
| ST5 Day 85 | 3.9 (2.7 to 5.6) | 4.5 (3.1 to 6.4) | 1.0 (1.0 to 1.0) |
| ST5 Day 180 | 1.3 (1.0 to 1.6) | 1.3 (1.1 to 1.6) | 1.0 (1.0 to 1.0) |
| ST5 Day 208 | 14.0 (9.3 to 21.2) | 16.9 (10.2 to 27.8) | 1.0 (1.0 to 1.0) |
| ST5 Day 365 | 2.5 (1.8 to 3.5) | 2.2 (1.5 to 3.2) | 1.0 (1.0 to 1.0) |
| ST5 Day 545 | 1.5 (1.2 to 1.9) | 1.4 (1.1 to 1.8) | 1.0 (1.0 to 1.0) |
| ST6 Day 29 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.1) | 1.0 (0.8 to 1.2) |
| ST6 Day 57 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.0 (0.8 to 1.3) |
| ST6 Day 85 | 3.2 (2.2 to 4.5) | 3.9 (2.7 to 5.7) | 0.9 (0.8 to 1.1) |
| ST6 Day 180 | 1.5 (1.2 to 1.8) | 1.5 (1.2 to 1.9) | 1.0 (0.8 to 1.3) |
| ST6 Day 208 | 13.9 (8.7 to 22.2) | 17.3 (10.7 to 28.0) | 1.0 (0.7 to 1.3) |
| ST6 Day 365 | 2.8 (1.9 to 4.0) | 2.7 (1.8 to 4.0) | 1.0 (0.8 to 1.2) |
| ST6 Day 545 | 1.4 (1.1 to 1.8) | 1.5 (1.2 to 2.0) | 0.9 (0.7 to 1.1) |
SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) During the Main Study Phase | 4.1 (1.6 to 10.1) | 4.1 (1.6 to 10.0) | 3.9 (1.1 to 13.2) |
SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| Percentage of Participants With Related SAEs During the Main Study Phase | 0.0 (0.0 to 3.8) | 0.0 (0.0 to 3.8) | 0.0 (0.0 to 7.0) |
AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| Percentage of Participants Adverse Event of Special Interest (AESIs) During the Main Study Phase | 2.1 (0.6 to 7.2) | 0.0 (0.0 to 3.8) | 0.0 (0.0 to 7.0) |
AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| Percentage of Participants With Related AESIs During the Main Study Phase | 1.0 (0.2 to 5.6) | 0.0 (0.0 to 3.8) | 0.0 (0.0 to 7.0) |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| Percentage of Participants With Unsolicited AEs During the Main Study Phase | 66.0 (56.1 to 74.6) | 64.3 (54.4 to 73.1) | 68.6 (55.0 to 79.7) |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| Percentage of Participants With Related Unsolicited AEs During the Main Study Phase | 18.6 (12.1 to 27.4) | 22.4 (15.3 to 31.7) | 7.8 (3.1 to 18.5) |
Solicited local AEs included pain, tenderness, induration (hardening), swelling and erythema (redness). Solicited systemic AEs included headache, myalgia (muscle pain), arthralgia (joint pain), fever (oral body temperature), flu-like symptoms, nausea, vomiting and fatigue. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| Any solicited local AE: Any vaccination | 95.9 (89.9 to 98.4) | 98.0 (92.9 to 99.4) | 45.1 (32.3 to 58.6) |
| Solicited local AE: 1st vaccination | 94.8 (88.5 to 97.8) | 93.9 (87.3 to 97.2) | 25.5 (15.5 to 38.9) |
| Solicited local AE: 2nd vaccination | 80.4 (71.4 to 87.1) | 83.7 (75.1 to 89.7) | 23.5 (14.0 to 36.8) |
| Solicited local AE: 3rd vaccination | 78.4 (69.2 to 85.4) | 82.7 (74.0 to 88.9) | 17.6 (9.6 to 30.3) |
| Any solicited systemic AE: Any vaccination | 78.4 (69.2 to 85.4) | 69.4 (59.7 to 77.6) | 51.0 (37.7 to 64.1) |
| Solicited systemic AE: 1st vaccination | 61.9 (51.9 to 70.9) | 56.1 (46.3 to 65.5) | 35.3 (23.6 to 49.0) |
| Solicited systemic AE: 2nd vaccination | 47.4 (37.8 to 57.3) | 40.8 (31.6 to 50.7) | 21.6 (12.5 to 34.6) |
| Solicited systemic AE: 3rd vaccination | 36.1 (27.2 to 46.0) | 40.8 (31.6 to 50.7) | 17.6 (9.6 to 30.3) |
Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs during main study phase stratified by age group 18-49 years and 50-65 years were reported. SAE: any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. AESI: any AEs of scientific/medical concern specific to study vaccine. Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AE: any untoward medical occurrence in participant associated with use of study vaccine, whether or not related to study vaccine, reported in addition to solicited and any solicited symptom with onset outside specified period of follow-up. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo |
|---|---|---|---|
| SAE: 18-49 Years | 3.1 (0.9 to 10.7) | 3.1 (0.9 to 10.7) | 0.0 (0.0 to 10.7) |
| SAE: 50-65 Years | 6.1 (1.7 to 19.6) | 5.9 (1.6 to 19.1) | 10.5 (2.9 to 31.4) |
| AESI: 18-49 Years | 3.1 (0.9 to 10.7) | 0.0 (0.0 to 5.7) | 0.0 (0.0 to 10.7) |
| AESI: 50-65 Years | 0.0 (0.0 to 10.4) | 0.0 (0.0 to 10.2) | 0.0 (0.0 to 16.8) |
| Solicited AE: 18-49 Years | 95.3 (87.1 to 98.4) | 96.9 (89.3 to 99.1) | 59.4 (42.3 to 74.5) |
| Solicited AE: 50-65 Years | 100 (89.6 to 100) | 100 (89.8 to 100) | 73.7 (51.2 to 88.2) |
| Unsolicited AE: 18-49 Years | 64.1 (51.8 to 74.7) | 65.6 (53.4 to 76.1) | 59.4 (42.3 to 74.5) |
| Unsolicited AE: 50-65 Years | 69.7 (52.7 to 82.6) | 61.8 (45.0 to 76.1) | 84.2 (62.4 to 94.5) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
| Units per milliliter (U/mL) | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| ST1 Day 1 | 20.5 (19.5 to 21.4) | 20.0 (20.0 to 20.0) |
| ST1 Day 29 | 20.9 (19.6 to 22.3) | 20.0 (20.0 to 20.0) |
| ST1 Day 57 | 22.6 (19.8 to 25.8) | 20.0 (20.0 to 20.0) |
| ST1 Day 85 | 78.9 (53.2 to 117.1) | 67.2 (41.2 to 109.6) |
| ST1 Day 180 | 27.6 (23.4 to 32.5) | 24.2 (19.4 to 30.3) |
| ST1 Day 208 | 292.0 (198.1 to 430.3) | 349.5 (184.4 to 662.4) |
| ST1 Day 365 | 39.7 (30.0 to 52.4) | 37.3 (20.9 to 66.4) |
| ST1 Day 545 | 24.9 (21.2 to 29.2) | 24.0 (17.9 to 32.3) |
| ST1 Month 19 | 1277.0 (861.8 to 1892.3) | 23.6 (18.1 to 30.8) |
| ST1 Month 24 | 137.4 (95.8 to 196.9) | 22.3 (17.7 to 28.0) |
| ST1 Month 30 | 54.1 (38.6 to 75.7) | 22.1 (17.9 to 27.4) |
| ST2 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 29 | 23.4 (20.0 to 27.2) | 20.0 (20.0 to 20.0) |
| ST2 Day 57 | 23.2 (19.3 to 27.8) | 20.0 (20.0 to 20.0) |
| ST2 Day 85 | 219.3 (156.5 to 307.4) | 187.4 (109.2 to 321.8) |
| ST2 Day 180 | 41.0 (31.1 to 54.1) | 33.5 (22.9 to 48.8) |
| ST2 Day 208 | 606.3 (419.0 to 877.3) | 694.7 (427.9 to 1127.9) |
| ST2 Day 365 | 76.1 (55.0 to 105.5) | 75.5 (44.0 to 129.6) |
| ST2 Day 545 | 31.8 (25.2 to 40.1) | 35.9 (25.2 to 51.2) |
| ST2 Month 19 | 2194.5 (1566.8 to 3073.7) | 36.8 (26.4 to 51.3) |
| ST2 Month 24 | 258.6 (197.4 to 338.8) | 26.0 (19.9 to 34.1) |
| ST2 Month 30 | 89.5 (63.4 to 126.2) | 21.9 (18.0 to 26.6) |
| ST3 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 29 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 57 | 21.8 (18.3 to 25.9) | 20.0 (20.0 to 20.0) |
| ST3 Day 85 | 235.1 (155.9 to 354.3) | 237.6 (152.4 to 370.4) |
| ST3 Day 180 | 47.6 (36.7 to 61.7) | 43.9 (28.0 to 68.8) |
| ST3 Day 208 | 631.9 (431.2 to 925.9) | 666.3 (393.9 to 1127.3) |
| ST3 Day 365 | 78.7 (57.2 to 108.3) | 81.1 (44.0 to 149.7) |
| ST3 Day 545 | 31.1 (24.8 to 38.8) | 39.5 (25.9 to 60.4) |
| ST3 Month 19 | 1916.2 (1320.7 to 2780.2) | 35.8 (24.9 to 51.7) |
| ST3 Month 24 | 265.8 (202.9 to 348.2) | 29.1 (20.8 to 40.6) |
| ST3 Month 30 | 101.6 (77.6 to 133.1) | 24.9 (19.0 to 32.6) |
| ST4 Day 1 | 20.8 (19.2 to 22.4) | 20.0 (20.0 to 20.0) |
| ST4 Day 29 | 21.2 (19.5 to 23.1) | 20.0 (20.0 to 20.0) |
| ST4 Day 57 | 22.2 (19.6 to 25.1) | 20.0 (20.0 to 20.0) |
| ST4 Day 85 | 108.9 (75.9 to 156.3) | 100.7 (65.1 to 155.6) |
| ST4 Day 180 | 30.1 (24.7 to 36.6) | 28.4 (21.2 to 38.2) |
| ST4 Day 208 | 376.6 (261.1 to 543.3) | 455.3 (268.2 to 773.1) |
| ST4 Day 365 | 47.5 (35.8 to 62.9) | 46.5 (26.7 to 80.9) |
| ST4 Day 545 | 28.8 (23.8 to 34.8) | 31.3 (22.5 to 43.7) |
| ST4 Month 19 | 1661.1 (1156.4 to 2386.0) | 26.5 (19.9 to 35.4) |
| ST4 Month 24 | 200.7 (150.9 to 266.8) | 24.6 (18.9 to 32.0) |
| ST4 Month 30 | 72.3 (52.2 to 100.1) | 22.1 (17.9 to 27.3) |
| ST5 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST5 Day 29 | 22.1 (19.5 to 25.0) | 20.0 (20.0 to 20.0) |
| ST5 Day 57 | 23.3 (19.7 to 27.5) | 20.0 (20.0 to 20.0) |
| ST5 Day 85 | 100.9 (70.6 to 144.1) | 127.4 (85.5 to 189.8) |
| ST5 Day 180 | 26.5 (22.3 to 31.6) | 32.3 (23.4 to 44.7) |
| ST5 Day 208 | 370.6 (257.3 to 533.8) | 528.4 (330.8 to 844.0) |
| ST5 Day 365 | 43.9 (32.5 to 59.3) | 59.4 (35.9 to 98.4) |
| ST5 Day 545 | 25.0 (21.1 to 29.7) | 31.1 (22.0 to 44.0) |
| ST5 Month 19 | 1507.9 (1066.0 to 2133.0) | 25.5 (19.2 to 33.8) |
| ST5 Month 24 | 170.2 (127.2 to 227.7) | 23.7 (18.5 to 30.3) |
| ST5 Month 30 | 74.0 (54.9 to 99.7) | 23.6 (18.6 to 29.9) |
| ST6 Day 1 | 20.9 (19.2 to 22.7) | 20.0 (20.0 to 20.0) |
| ST6 Day 29 | 22.0 (19.6 to 24.7) | 20.0 (20.0 to 20.0) |
| ST6 Day 57 | 24.8 (20.7 to 29.9) | 20.0 (20.0 to 20.0) |
| ST6 Day 85 | 82.0 (57.3 to 117.3) | 116.5 (74.3 to 182.5) |
| ST6 Day 180 | 29.2 (23.8 to 35.7) | 36.4 (25.4 to 52.2) |
| ST6 Day 208 | 351.9 (246.7 to 502.0) | 509.0 (308.6 to 839.4) |
| ST6 Day 365 | 46.8 (33.7 to 65.0) | 67.3 (41.6 to 108.7) |
| ST6 Day 545 | 26.3 (21.6 to 32.0) | 29.1 (21.0 to 40.4) |
| ST6 Month 19 | 1406.8 (996.2 to 1986.7) | 28.7 (21.1 to 39.2) |
| ST6 Month 24 | 181.5 (138.9 to 237.1) | 25.8 (19.9 to 33.5) |
| ST6 Month 30 | 76.0 (55.7 to 103.8) | 23.8 (18.4 to 30.6) |
SCR for each OspA serotype specific IgG ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): greater than or equal to (\>=) 4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. Percentages are based on the number of participants with non-missing observations. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| ST1 Day 29 | 2.7 (0.5 to 13.8) | 0.0 (0.0 to 17.6) |
| ST1 Day 57 | 8.1 (2.8 to 21.3) | 0.0 (0.0 to 17.6) |
| ST1 Day 85 | 64.9 (48.8 to 78.2) | 70.6 (46.9 to 86.7) |
| ST1 Day 180 | 29.7 (17.5 to 45.8) | 16.7 (5.8 to 39.2) |
| ST1 Day 208 | 97.1 (85.5 to 99.5) | 100 (81.6 to 100) |
| ST1 Day 365 | 43.2 (28.7 to 59.1) | 29.4 (13.3 to 53.1) |
| ST1 Day 545 | 16.2 (7.7 to 31.1) | 11.1 (3.1 to 32.8) |
| ST1 Month 19 | 100 (90.6 to 100) | 11.1 (3.1 to 32.8) |
| ST1 Month 24 | 89.2 (75.3 to 95.7) | 5.9 (1.0 to 27.0) |
| ST1 Month 30 | 56.8 (40.9 to 71.3) | 5.9 (1.0 to 27.0) |
| ST2 Day 29 | 10.8 (4.3 to 24.7) | 0.0 (0.0 to 17.6) |
| ST2 Day 57 | 8.1 (2.8 to 21.3) | 0.0 (0.0 to 17.6) |
| ST2 Day 85 | 97.3 (86.2 to 99.5) | 88.2 (65.7 to 96.7) |
| ST2 Day 180 | 48.6 (33.4 to 64.1) | 33.3 (16.3 to 56.3) |
| ST2 Day 208 | 97.1 (85.5 to 99.5) | 100 (81.6 to 100) |
| ST2 Day 365 | 75.7 (59.9 to 86.6) | 70.6 (46.9 to 86.7) |
| ST2 Day 545 | 35.1 (21.8 to 51.2) | 44.4 (24.6 to 66.3) |
| ST2 Month 19 | 100 (90.6 to 100) | 50.0 (29.0 to 71.0) |
| ST2 Month 24 | 100 (90.6 to 100) | 23.5 (9.6 to 47.3) |
| ST2 Month 30 | 73.0 (57.0 to 84.6) | 5.9 (1.0 to 27.0) |
| ST3 Day 29 | 0.0 (0.0 to 9.4) | 0.0 (0.0 to 17.6) |
| ST3 Day 57 | 2.7 (0.5 to 13.8) | 0.0 (0.0 to 17.6) |
| ST3 Day 85 | 89.2 (75.3 to 95.7) | 100 (81.6 to 100) |
| ST3 Day 180 | 59.5 (43.5 to 73.7) | 50.0 (29.0 to 71.0) |
| ST3 Day 208 | 97.1 (85.5 to 99.5) | 100 (81.6 to 100) |
| ST3 Day 365 | 73.0 (57.0 to 84.6) | 70.6 (46.9 to 86.7) |
| ST3 Day 545 | 32.4 (19.6 to 48.5) | 44.4 (24.6 to 66.3) |
| ST3 Month 19 | 100 (90.6 to 100) | 44.4 (24.6 to 66.3) |
| ST3 Month 24 | 100 (90.6 to 100) | 29.4 (13.3 to 53.1) |
| ST3 Month 30 | 89.2 (75.3 to 95.7) | 17.6 (6.2 to 41.0) |
| ST4 Day 29 | 2.7 (0.5 to 13.8) | 0.0 (0.0 to 17.6) |
| ST4 Day 57 | 5.4 (1.5 to 17.7) | 0.0 (0.0 to 17.6) |
| ST4 Day 85 | 81.1 (65.8 to 90.5) | 88.2 (65.7 to 96.7) |
| ST4 Day 180 | 32.4 (19.6 to 48.5) | 27.8 (12.5 to 50.9) |
| ST4 Day 208 | 97.1 (85.5 to 99.5) | 100 (81.6 to 100) |
| ST4 Day 365 | 56.8 (40.9 to 71.3) | 52.9 (31.0 to 73.8) |
| ST4 Day 545 | 29.7 (17.5 to 45.8) | 38.9 (20.3 to 61.4) |
| ST4 Month 19 | 100 (90.6 to 100) | 22.2 (9.0 to 45.2) |
| ST4 Month 24 | 100 (90.6 to 100) | 17.6 (6.2 to 41.0) |
| ST4 Month 30 | 73.0 (57.0 to 84.6) | 5.9 (1.0 to 27.0) |
| ST5 Day 29 | 8.1 (2.8 to 21.3) | 0.0 (0.0 to 17.6) |
| ST5 Day 57 | 10.8 (4.3 to 24.7) | 0.0 (0.0 to 17.6) |
| ST5 Day 85 | 78.4 (62.8 to 88.6) | 94.1 (73.0 to 99.0) |
| ST5 Day 180 | 24.3 (13.4 to 40.1) | 38.9 (20.3 to 61.4) |
| ST5 Day 208 | 97.1 (85.5 to 99.5) | 100 (81.6 to 100) |
| ST5 Day 365 | 48.6 (33.4 to 64.1) | 70.6 (46.9 to 86.7) |
| ST5 Day 545 | 18.9 (9.5 to 34.2) | 33.3 (16.3 to 56.3) |
| ST5 Month 19 | 100 (90.6 to 100) | 16.7 (5.8 to 39.2) |
| ST5 Month 24 | 97.3 (86.2 to 99.5) | 11.8 (3.3 to 34.3) |
| ST5 Month 30 | 81.1 (65.8 to 90.5) | 11.8 (3.3 to 34.3) |
| ST6 Day 29 | 5.4 (1.5 to 17.7) | 0.0 (0.0 to 17.6) |
| ST6 Day 57 | 13.5 (5.9 to 28.0) | 0.0 (0.0 to 17.6) |
| ST6 Day 85 | 70.3 (54.2 to 82.5) | 88.2 (65.7 to 96.7) |
| ST6 Day 180 | 27.0 (15.4 to 43.0) | 44.4 (24.6 to 66.3) |
| ST6 Day 208 | 97.1 (85.5 to 99.5) | 100 (81.6 to 100) |
| ST6 Day 365 | 45.9 (31.0 to 61.6) | 76.5 (52.7 to 90.4) |
| ST6 Day 545 | 16.2 (7.7 to 31.1) | 27.8 (12.5 to 50.9) |
| ST6 Month 19 | 100 (90.6 to 100) | 27.8 (12.5 to 50.9) |
| ST6 Month 24 | 97.3 (86.2 to 99.5) | 23.5 (9.6 to 47.3) |
| ST6 Month 30 | 73.0 (57.0 to 84.6) | 11.8 (3.3 to 34.3) |
GMFR as compared to baseline for IgG against each Osp serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 were reported in this outcome measure. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
| Fold Rise | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| ST1 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST1 Day 57 | 1.1 (1.0 to 1.3) | 1.0 (1.0 to 1.0) |
| ST1 Day 85 | 3.9 (2.6 to 5.7) | 3.4 (2.1 to 5.5) |
| ST1 Day 180 | 1.3 (1.2 to 1.6) | 1.2 (1.0 to 1.5) |
| ST1 Day 208 | 14.2 (9.7 to 21.0) | 17.5 (9.2 to 33.1) |
| ST1 Day 365 | 1.9 (1.5 to 2.6) | 1.9 (1.0 to 3.3) |
| ST1 Day 545 | 1.2 (1.0 to 1.4) | 1.2 (0.9 to 1.6) |
| ST1 Month 19 | 62.4 (42.6 to 91.4) | 1.2 (0.9 to 1.5) |
| ST1 Month 24 | 6.7 (4.7 to 9.6) | 1.1 (0.9 to 1.4) |
| ST1 Month 30 | 2.6 (1.9 to 3.7) | 1.1 (0.9 to 1.4) |
| ST2 Day 29 | 1.2 (1.0 to 1.4) | 1.0 (1.0 to 1.0) |
| ST2 Day 57 | 1.2 (1.0 to 1.4) | 1.0 (1.0 to 1.0) |
| ST2 Day 85 | 11.0 (7.8 to 15.4) | 9.4 (5.5 to 16.1) |
| ST2 Day 180 | 2.1 (1.6 to 2.7) | 1.7 (1.1 to 2.4) |
| ST2 Day 208 | 30.3 (21.0 to 43.9) | 34.7 (21.4 to 56.4) |
| ST2 Day 365 | 3.8 (2.7 to 5.3) | 3.8 (2.2 to 6.5) |
| ST2 Day 545 | 1.6 (1.3 to 2.0) | 1.8 (1.3 to 2.6) |
| ST2 Month 19 | 109.7 (78.3 to 153.7) | 1.8 (1.3 to 2.6) |
| ST2 Month 24 | 12.9 (9.9 to 16.9) | 1.3 (1.0 to 1.7) |
| ST2 Month 30 | 4.5 (3.2 to 6.3) | 1.1 (0.9 to 1.3) |
| ST3 Day 29 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST3 Day 57 | 1.1 (0.9 to 1.3) | 1.0 (1.0 to 1.0) |
| ST3 Day 85 | 11.8 (7.8 to 17.7) | 11.9 (7.6 to 18.5) |
| ST3 Day 180 | 2.4 (1.8 to 3.1) | 2.2 (1.4 to 3.4) |
| ST3 Day 208 | 31.6 (21.6 to 46.3) | 33.3 (19.7 to 56.4) |
| ST3 Day 365 | 3.9 (2.9 to 5.4) | 4.1 (2.2 to 7.5) |
| ST3 Day 545 | 1.6 (1.2 to 1.9) | 2.0 (1.3 to 3.0) |
| ST3 Month 19 | 95.8 (66.0 to 139.0) | 1.8 (1.2 to 2.6) |
| ST3 Month 24 | 13.3 (10.1 to 17.4) | 1.5 (1.0 to 2.0) |
| ST3 Month 30 | 5.1 (3.9 to 6.7) | 1.2 (0.9 to 1.6) |
| ST4 Day 29 | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST4 Day 57 | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.0) |
| ST4 Day 85 | 5.2 (3.7 to 7.4) | 5.0 (3.3 to 7.8) |
| ST4 Day 180 | 1.4 (1.2 to 1.7) | 1.4 (1.1 to 1.9) |
| ST4 Day 208 | 18.1 (12.6 to 25.9) | 22.8 (13.4 to 38.7) |
| ST4 Day 365 | 2.3 (1.7 to 3.0) | 2.3 (1.3 to 4.0) |
| ST4 Day 545 | 1.4 (1.2 to 1.6) | 1.6 (1.1 to 2.2) |
| ST4 Month 19 | 79.9 (56.5 to 113.1) | 1.3 (1.0 to 1.8) |
| ST4 Month 24 | 9.7 (7.3 to 12.8) | 1.2 (0.9 to 1.6) |
| ST4 Month 30 | 3.5 (2.5 to 4.8) | 1.1 (0.9 to 1.4) |
| ST5 Day 29 | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.0) |
| ST5 Day 57 | 1.2 (1.0 to 1.4) | 1.0 (1.0 to 1.0) |
| ST5 Day 85 | 5.0 (3.5 to 7.2) | 6.4 (4.3 to 9.5) |
| ST5 Day 180 | 1.3 (1.1 to 1.6) | 1.6 (1.2 to 2.2) |
| ST5 Day 208 | 18.5 (12.9 to 26.7) | 26.4 (16.5 to 42.2) |
| ST5 Day 365 | 2.2 (1.6 to 3.0) | 3.0 (1.8 to 4.9) |
| ST5 Day 545 | 1.3 (1.1 to 1.5) | 1.6 (1.1 to 2.2) |
| ST5 Month 19 | 75.4 (53.3 to 106.7) | 1.3 (1.0 to 1.7) |
| ST5 Month 24 | 8.5 (6.4 to 11.4) | 1.2 (0.9 to 1.5) |
| ST5 Month 30 | 3.7 (2.7 to 5.0) | 1.2 (0.9 to 1.5) |
| ST6 Day 29 | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST6 Day 57 | 1.2 (1.0 to 1.4) | 1.0 (1.0 to 1.0) |
| ST6 Day 85 | 3.9 (2.8 to 5.6) | 5.8 (3.7 to 9.1) |
| ST6 Day 180 | 1.4 (1.2 to 1.7) | 1.8 (1.3 to 2.6) |
| ST6 Day 208 | 16.8 (11.8 to 24.0) | 25.4 (15.4 to 42.0) |
| ST6 Day 365 | 2.2 (1.6 to 3.1) | 3.4 (2.1 to 5.4) |
| ST6 Day 545 | 1.3 (1.1 to 1.5) | 1.5 (1.1 to 2.0) |
| ST6 Month 19 | 67.5 (48.4 to 94.0) | 1.4 (1.1 to 2.0) |
| ST6 Month 24 | 8.7 (6.7 to 11.4) | 1.3 (1.0 to 1.7) |
| ST6 Month 30 | 3.6 (2.7 to 4.9) | 1.2 (0.9 to 1.5) |
GMFR as compared to Day 208 for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Month 19, Month 24 and Month 30. The outcome measure was planned to be analyzed for Booster PP population from Day 208 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
| Fold Rise | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| ST1 Month 19 | 4.2 (3.4 to 5.2) | 0.1 (0.0 to 0.1) |
| ST1 Month 24 | 0.5 (0.4 to 0.6) | 0.1 (0.0 to 0.1) |
| ST1 Month 30 | 0.2 (0.1 to 0.2) | 0.1 (0.0 to 0.1) |
| ST2 Month 19 | 3.5 (2.9 to 4.3) | 0.1 (0.0 to 0.1) |
| ST2 Month 24 | 0.4 (0.3 to 0.5) | 0.0 (0.0 to 0.1) |
| ST2 Month 30 | 0.1 (0.1 to 0.2) | 0.0 (0.0 to 0.0) |
| ST3 Month 19 | 2.9 (2.3 to 3.5) | 0.1 (0.0 to 0.1) |
| ST3 Month 24 | 0.4 (0.3 to 0.5) | 0.0 (0.0 to 0.1) |
| ST3 Month 30 | 0.2 (0.1 to 0.2) | 0.0 (0.0 to 0.1) |
| ST4 Month 19 | 4.2 (3.5 to 5.1) | 0.1 (0.0 to 0.1) |
| ST4 Month 24 | 0.5 (0.4 to 0.7) | 0.1 (0.0 to 0.1) |
| ST4 Month 30 | 0.2 (0.1 to 0.3) | 0.0 (0.0 to 0.1) |
| ST5 Month 19 | 4.0 (3.3 to 4.8) | 0.0 (0.0 to 0.1) |
| ST5 Month 24 | 0.5 (0.4 to 0.6) | 0.0 (0.0 to 0.1) |
| ST5 Month 30 | 0.2 (0.1 to 0.3) | 0.0 (0.0 to 0.1) |
| ST6 Month 19 | 3.9 (3.2 to 4.7) | 0.1 (0.0 to 0.1) |
| ST6 Month 24 | 0.5 (0.4 to 0.7) | 0.1 (0.0 to 0.1) |
| ST6 Month 30 | 0.2 (0.2 to 0.3) | 0.0 (0.0 to 0.1) |
GMFR as compared to Month 18 (pre-booster) for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Month 19, Month 24 and Month 30. The outcome measure was planned to be analyzed for Booster PP population.
| Fold Rise | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| ST1 Month 19 | 51.3 (37.1 to 71.0) | 1.0 (1.0 to 1.0) |
| ST1 Month 24 | 5.5 (4.2 to 7.3) | 0.9 (0.8 to 1.0) |
| ST1 Month 30 | 2.2 (1.7 to 2.8) | 0.9 (0.8 to 1.0) |
| ST2 Month 19 | 69.1 (54.2 to 88.0) | 1.0 (0.9 to 1.2) |
| ST2 Month 24 | 8.1 (6.8 to 9.8) | 0.8 (0.6 to 0.9) |
| ST2 Month 30 | 2.8 (2.2 to 3.6) | 0.6 (0.5 to 0.9) |
| ST3 Month 19 | 61.7 (46.2 to 82.5) | 0.9 (0.8 to 1.0) |
| ST3 Month 24 | 8.6 (7.0 to 10.4) | 0.8 (0.6 to 1.0) |
| ST3 Month 30 | 3.3 (2.6 to 4.0) | 0.7 (0.5 to 0.9) |
| ST4 Month 19 | 57.7 (42.4 to 78.6) | 0.8 (0.7 to 1.0) |
| ST4 Month 24 | 7.0 (5.6 to 8.7) | 0.8 (0.7 to 1.0) |
| ST4 Month 30 | 2.5 (2.0 to 3.2) | 0.7 (0.6 to 0.9) |
| ST5 Month 19 | 60.2 (45.1 to 80.4) | 0.8 (0.7 to 1.0) |
| ST5 Month 24 | 6.8 (5.4 to 8.6) | 0.8 (0.7 to 1.0) |
| ST5 Month 30 | 3.0 (2.3 to 3.8) | 0.8 (0.7 to 1.0) |
| ST6 Month 19 | 53.5 (39.2 to 73.2) | 1.0 (0.8 to 1.2) |
| ST6 Month 24 | 6.9 (5.4 to 8.9) | 0.9 (0.9 to 1.0) |
| ST6 Month 30 | 2.9 (2.2 to 3.8) | 0.9 (0.7 to 1.0) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 18 - 49 years. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
| Units per milliliter (U/mL) | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| ST1 Day 1 | 20.8 (19.2 to 22.5) | 20.0 (20.0 to 20.0) |
| ST1 Day 29 | 21.6 (19.3 to 24.1) | 20.0 (20.0 to 20.0) |
| ST1 Day 57 | 22.5 (19.7 to 25.8) | 20.0 (20.0 to 20.0) |
| ST1 Day 85 | 103.1 (60.3 to 176.4) | 62.8 (33.6 to 117.4) |
| ST1 Day 180 | 29.2 (23.0 to 37.0) | 21.9 (18.0 to 26.7) |
| ST1 Day 208 | 335.9 (199.7 to 565.0) | 335.3 (189.4 to 593.7) |
| ST1 Day 365 | 39.3 (27.5 to 56.4) | 34.8 (20.6 to 58.7) |
| ST1 Day 545 | 24.6 (20.0 to 30.2) | 21.4 (18.4 to 24.9) |
| ST1 Month 19 | 1551.7 (943.9 to 2550.8) | 21.4 (18.5 to 24.8) |
| ST1 Month 24 | 142.1 (90.9 to 222.1) | 20.0 (20.0 to 20.0) |
| ST1 Month 30 | 56.4 (37.6 to 84.8) | 20.0 (20.0 to 20.0) |
| ST2 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 29 | 24.7 (19.3 to 31.7) | 20.0 (20.0 to 20.0) |
| ST2 Day 57 | 25.7 (18.9 to 35.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 85 | 252.1 (160.9 to 395.1) | 213.1 (110.0 to 412.8) |
| ST2 Day 180 | 43.0 (29.5 to 62.6) | 36.4 (22.4 to 59.3) |
| ST2 Day 208 | 608.9 (428.2 to 866.0) | 761.7 (531.8 to 1091.0) |
| ST2 Day 365 | 65.0 (44.5 to 94.8) | 88.8 (53.3 to 148.1) |
| ST2 Day 545 | 28.9 (22.6 to 37.0) | 38.3 (26.0 to 56.5) |
| ST2 Month 19 | 2199.0 (1423.5 to 3396.9) | 40.2 (28.0 to 57.7) |
| ST2 Month 24 | 230.4 (166.9 to 317.9) | 25.1 (19.3 to 32.7) |
| ST2 Month 30 | 72.8 (45.9 to 115.3) | 20.0 (20.0 to 20.0) |
| ST3 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 29 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 57 | 23.1 (17.1 to 31.1) | 20.0 (20.0 to 20.0) |
| ST3 Day 85 | 280.1 (162.1 to 483.9) | 266.8 (154.9 to 459.4) |
| ST3 Day 180 | 52.8 (37.8 to 73.9) | 45.9 (26.6 to 79.4) |
| ST3 Day 208 | 710.0 (476.3 to 1058.3) | 696.6 (449.8 to 1078.7) |
| ST3 Day 365 | 78.1 (53.2 to 114.6) | 91.0 (50.6 to 163.7) |
| ST3 Day 545 | 30.4 (22.7 to 40.7) | 41.5 (27.0 to 63.7) |
| ST3 Month 19 | 1997.3 (1280.0 to 3116.6) | 37.5 (25.6 to 55.0) |
| ST3 Month 24 | 246.0 (174.9 to 346.2) | 28.3 (20.3 to 39.5) |
| ST3 Month 30 | 96.3 (68.9 to 134.8) | 23.3 (18.5 to 29.2) |
| ST4 Day 1 | 21.3 (18.7 to 24.4) | 20.0 (20.0 to 20.0) |
| ST4 Day 29 | 22.0 (19.1 to 25.5) | 20.0 (20.0 to 20.0) |
| ST4 Day 57 | 23.8 (19.3 to 29.4) | 20.0 (20.0 to 20.0) |
| ST4 Day 85 | 134.8 (82.5 to 220.4) | 105.4 (61.4 to 180.8) |
| ST4 Day 180 | 31.1 (23.5 to 41.1) | 29.5 (20.3 to 43.0) |
| ST4 Day 208 | 432.0 (288.2 to 647.4) | 458.6 (306.9 to 685.3) |
| ST4 Day 365 | 45.8 (31.9 to 65.8) | 47.3 (29.9 to 74.9) |
| ST4 Day 545 | 29.3 (22.8 to 37.5) | 28.6 (21.4 to 38.2) |
| ST4 Month 19 | 1817.7 (1179.3 to 2801.5) | 25.4 (19.3 to 33.4) |
| ST4 Month 24 | 191.7 (138.8 to 264.8) | 22.8 (18.7 to 27.8) |
| ST4 Month 30 | 66.8 (44.8 to 99.5) | 20.0 (20.0 to 20.0) |
| ST5 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST5 Day 29 | 21.0 (19.0 to 23.1) | 20.0 (20.0 to 20.0) |
| ST5 Day 57 | 23.6 (18.1 to 30.6) | 20.0 (20.0 to 20.0) |
| ST5 Day 85 | 120.6 (74.6 to 195.0) | 122.6 (70.7 to 212.7) |
| ST5 Day 180 | 27.4 (21.5 to 34.9) | 31.9 (21.4 to 47.4) |
| ST5 Day 208 | 380.7 (238.8 to 607.1) | 506.8 (323.4 to 794.1) |
| ST5 Day 365 | 42.5 (29.7 to 60.9) | 55.0 (32.7 to 92.6) |
| ST5 Day 545 | 25.1 (20.5 to 30.7) | 31.6 (21.5 to 46.5) |
| ST5 Month 19 | 1600.5 (1002.8 to 2554.6) | 24.4 (18.1 to 32.8) |
| ST5 Month 24 | 160.2 (109.5 to 234.3) | 22.2 (17.6 to 27.9) |
| ST5 Month 30 | 78.1 (57.1 to 106.7) | 22.3 (17.6 to 28.1) |
| ST6 Day 1 | 21.5 (18.5 to 24.8) | 20.0 (20.0 to 20.0) |
| ST6 Day 29 | 22.7 (18.9 to 27.3) | 20.0 (20.0 to 20.0) |
| ST6 Day 57 | 27.3 (20.4 to 36.5) | 20.0 (20.0 to 20.0) |
| ST6 Day 85 | 90.2 (53.9 to 151.0) | 121.4 (72.1 to 204.5) |
| ST6 Day 180 | 28.5 (21.7 to 37.5) | 34.4 (21.8 to 54.1) |
| ST6 Day 208 | 346.1 (217.3 to 551.1) | 502.5 (314.1 to 803.8) |
| ST6 Day 365 | 42.8 (28.7 to 63.8) | 63.1 (38.1 to 104.4) |
| ST6 Day 545 | 25.4 (20.0 to 32.4) | 28.7 (20.3 to 40.6) |
| ST6 Month 19 | 1449.3 (878.4 to 2391.3) | 28.7 (20.3 to 40.6) |
| ST6 Month 24 | 163.8 (115.0 to 233.2) | 25.1 (19.1 to 32.8) |
| ST6 Month 30 | 69.6 (48.1 to 100.7) | 22.1 (17.7 to 27.7) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 1 (Month 0), 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 50 - 65 years. The outcome measure was planned to be analyzed for Booster PP population from Day 1 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
| Units per milliliter (U/mL) | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| ST1 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST1 Day 29 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST1 Day 57 | 22.8 (17.2 to 30.3) | 20.0 (20.0 to 20.0) |
| ST1 Day 85 | 53.3 (29.6 to 95.9) | 78.8 (24.0 to 259.4) |
| ST1 Day 180 | 25.4 (20.2 to 31.9) | 31.6 (14.3 to 69.6) |
| ST1 Day 208 | 236.6 (124.2 to 450.7) | 386.0 (32.8 to 4546.3) |
| ST1 Day 365 | 40.2 (24.4 to 66.0) | 44.1 (4.9 to 396.6) |
| ST1 Day 545 | 25.3 (19.0 to 33.8) | 32.3 (8.5 to 122.8) |
| ST1 Month 19 | 959.7 (482.2 to 1910.2) | 30.7 (9.4 to 100.7) |
| ST1 Month 24 | 130.8 (66.8 to 256.0) | 28.8 (10.5 to 79.3) |
| ST1 Month 30 | 50.8 (26.7 to 96.6) | 28.2 (10.8 to 73.5) |
| ST2 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 29 | 21.4 (18.5 to 24.9) | 20.0 (20.0 to 20.0) |
| ST2 Day 57 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST2 Day 85 | 178.8 (102.1 to 313.1) | 137.8 (33.9 to 559.6) |
| ST2 Day 180 | 38.3 (24.2 to 60.5) | 26.8 (11.9 to 60.2) |
| ST2 Day 208 | 602.4 (260.7 to 1391.7) | 557.0 (75.6 to 4104.2) |
| ST2 Day 365 | 96.1 (51.6 to 179.2) | 51.1 (7.6 to 344.7) |
| ST2 Day 545 | 36.5 (22.5 to 59.2) | 30.4 (9.5 to 96.6) |
| ST2 Month 19 | 2187.9 (1198.0 to 3995.8) | 29.3 (10.2 to 84.1) |
| ST2 Month 24 | 306.4 (184.2 to 509.5) | 28.4 (10.7 to 75.4) |
| ST2 Month 30 | 121.2 (70.6 to 207.9) | 27.3 (11.5 to 64.9) |
| ST3 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 29 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 57 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST3 Day 85 | 181.8 (92.4 to 357.8) | 179.8 (57.8 to 559.6) |
| ST3 Day 180 | 40.8 (26.0 to 64.1) | 39.0 (11.4 to 133.7) |
| ST3 Day 208 | 530.4 (234.5 to 1199.8) | 599.0 (73.4 to 4891.0) |
| ST3 Day 365 | 79.7 (43.1 to 147.3) | 61.6 (6.7 to 566.4) |
| ST3 Day 545 | 32.1 (21.6 to 47.6) | 34.9 (7.4 to 163.5) |
| ST3 Month 19 | 1803.1 (878.3 to 3701.5) | 31.8 (8.8 to 115.6) |
| ST3 Month 24 | 297.8 (183.0 to 484.6) | 30.9 (9.3 to 102.9) |
| ST3 Month 30 | 109.9 (66.6 to 181.3) | 29.2 (10.2 to 83.7) |
| ST4 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST4 Day 29 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST4 Day 57 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST4 Day 85 | 79.7 (45.8 to 138.7) | 90.2 (28.5 to 285.4) |
| ST4 Day 180 | 28.6 (21.4 to 38.4) | 25.8 (12.8 to 52.1) |
| ST4 Day 208 | 306.6 (144.9 to 648.8) | 447.5 (49.6 to 4039.3) |
| ST4 Day 365 | 50.0 (30.2 to 82.7) | 44.5 (4.8 to 411.4) |
| ST4 Day 545 | 28.1 (20.1 to 39.2) | 39.7 (10.8 to 146.7) |
| ST4 Month 19 | 1455.5 (726.5 to 2916.0) | 29.8 (9.9 to 89.8) |
| ST4 Month 24 | 214.6 (121.0 to 380.7) | 29.3 (10.2 to 84.1) |
| ST4 Month 30 | 81.2 (44.1 to 149.3) | 28.1 (10.9 to 72.0) |
| ST5 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST5 Day 29 | 23.8 (17.9 to 31.8) | 20.0 (20.0 to 20.0) |
| ST5 Day 57 | 22.8 (18.7 to 27.8) | 20.0 (20.0 to 20.0) |
| ST5 Day 85 | 77.7 (44.0 to 137.0) | 139.8 (69.1 to 282.8) |
| ST5 Day 180 | 25.4 (19.2 to 33.6) | 33.5 (13.8 to 81.4) |
| ST5 Day 208 | 356.0 (182.9 to 693.0) | 584.1 (104.2 to 3275.4) |
| ST5 Day 365 | 45.9 (25.7 to 82.1) | 71.6 (12.7 to 403.9) |
| ST5 Day 545 | 24.9 (17.8 to 34.9) | 30.0 (9.8 to 92.1) |
| ST5 Month 19 | 1381.6 (772.7 to 2470.1) | 28.5 (10.7 to 75.9) |
| ST5 Month 24 | 186.0 (111.8 to 309.2) | 27.6 (11.3 to 67.4) |
| ST5 Month 30 | 68.3 (36.3 to 128.6) | 27.0 (11.7 to 62.3) |
| ST6 Day 1 | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| ST6 Day 29 | 21.1 (18.8 to 23.6) | 20.0 (20.0 to 20.0) |
| ST6 Day 57 | 21.7 (18.3 to 25.7) | 20.0 (20.0 to 20.0) |
| ST6 Day 85 | 71.4 (42.1 to 120.9) | 105.4 (27.3 to 407.4) |
| ST6 Day 180 | 30.1 (21.4 to 42.4) | 42.2 (17.5 to 102.0) |
| ST6 Day 208 | 360.9 (192.4 to 676.9) | 525.1 (80.5 to 3426.2) |
| ST6 Day 365 | 53.4 (28.8 to 98.9) | 78.6 (15.5 to 398.1) |
| ST6 Day 545 | 27.6 (19.0 to 40.0) | 30.2 (9.6 to 95.3) |
| ST6 Month 19 | 1346.7 (811.0 to 2236.3) | 28.8 (10.5 to 79.3) |
| ST6 Month 24 | 210.9 (134.5 to 330.8) | 27.7 (11.2 to 68.5) |
| ST6 Month 30 | 86.5 (47.6 to 157.4) | 28.1 (10.9 to 72.5) |
SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24 and Month 30 stratified by age group: 18 - 49 years was presented in this outcome measure. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| ST1 Day 29 | 4.5 (0.8 to 21.8) | 0.0 (0.0 to 22.8) |
| ST1 Day 57 | 9.1 (2.5 to 27.8) | 0.0 (0.0 to 22.8) |
| ST1 Day 85 | 72.7 (51.8 to 86.8) | 66.7 (39.1 to 86.2) |
| ST1 Day 180 | 31.8 (16.4 to 52.7) | 7.7 (1.4 to 33.3) |
| ST1 Day 208 | 95.2 (77.3 to 99.2) | 100 (75.8 to 100) |
| ST1 Day 365 | 40.9 (23.3 to 61.3) | 33.3 (13.8 to 60.9) |
| ST1 Day 545 | 13.6 (4.7 to 33.3) | 7.7 (1.4 to 33.3) |
| ST1 Month 19 | 100 (85.1 to 100) | 7.7 (1.4 to 33.3) |
| ST1 Month 24 | 90.9 (72.2 to 97.5) | 0.0 (0.0 to 24.2) |
| ST1 Month 30 | 63.6 (43.0 to 80.3) | 0.0 (0.0 to 24.2) |
| ST2 Day 29 | 13.6 (4.7 to 33.3) | 0.0 (0.0 to 22.8) |
| ST2 Day 57 | 13.6 (4.7 to 33.3) | 0.0 (0.0 to 22.8) |
| ST2 Day 85 | 100 (85.1 to 100) | 91.7 (64.6 to 98.5) |
| ST2 Day 180 | 50.0 (30.7 to 69.3) | 38.5 (17.7 to 64.5) |
| ST2 Day 208 | 100 (84.5 to 100) | 100 (75.8 to 100) |
| ST2 Day 365 | 72.7 (51.8 to 86.8) | 83.3 (55.2 to 95.3) |
| ST2 Day 545 | 31.8 (16.4 to 52.7) | 53.8 (29.1 to 76.8) |
| ST2 Month 19 | 100 (85.1 to 100) | 61.5 (35.5 to 82.3) |
| ST2 Month 24 | 100 (85.1 to 100) | 25.0 (8.9 to 53.2) |
| ST2 Month 30 | 63.6 (43.0 to 80.3) | 0.0 (0.0 to 24.2) |
| ST3 Day 29 | 0.0 (0.0 to 14.9) | 0.0 (0.0 to 22.8) |
| ST3 Day 57 | 4.5 (0.8 to 21.8) | 0.0 (0.0 to 22.8) |
| ST3 Day 85 | 90.9 (72.2 to 97.5) | 100 (75.8 to 100) |
| ST3 Day 180 | 68.2 (47.3 to 83.6) | 53.8 (29.1 to 76.8) |
| ST3 Day 208 | 100 (84.5 to 100) | 100 (75.8 to 100) |
| ST3 Day 365 | 77.3 (56.6 to 89.9) | 83.3 (55.2 to 95.3) |
| ST3 Day 545 | 31.8 (16.4 to 52.7) | 53.8 (29.1 to 76.8) |
| ST3 Month 19 | 100 (85.1 to 100) | 53.8 (29.1 to 76.8) |
| ST3 Month 24 | 100 (85.1 to 100) | 33.3 (13.8 to 60.9) |
| ST3 Month 30 | 90.9 (72.2 to 97.5) | 16.7 (4.7 to 44.8) |
| ST4 Day 29 | 4.5 (0.8 to 21.8) | 0.0 (0.0 to 22.8) |
| ST4 Day 57 | 9.1 (2.5 to 27.8) | 0.0 (0.0 to 22.8) |
| ST4 Day 85 | 86.4 (66.7 to 95.3) | 91.7 (64.6 to 98.5) |
| ST4 Day 180 | 31.8 (16.4 to 52.7) | 30.8 (12.7 to 57.6) |
| ST4 Day 208 | 100 (84.5 to 100) | 100 (75.8 to 100) |
| ST4 Day 365 | 54.5 (34.7 to 73.1) | 66.7 (39.1 to 86.2) |
| ST4 Day 545 | 31.8 (16.4 to 52.7) | 38.5 (17.7 to 64.5) |
| ST4 Month 19 | 100 (85.1 to 100) | 23.1 (8.2 to 50.3) |
| ST4 Month 24 | 100 (85.1 to 100) | 16.7 (4.7 to 44.8) |
| ST4 Month 30 | 68.2 (47.3 to 83.6) | 0.0 (0.0 to 24.2) |
| ST5 Day 29 | 4.5 (0.8 to 21.8) | 0.0 (0.0 to 22.8) |
| ST5 Day 57 | 9.1 (2.5 to 27.8) | 0.0 (0.0 to 22.8) |
| ST5 Day 85 | 81.8 (61.5 to 92.7) | 91.7 (64.6 to 98.5) |
| ST5 Day 180 | 27.3 (13.2 to 48.2) | 38.5 (17.7 to 64.5) |
| ST5 Day 208 | 95.2 (77.3 to 99.2) | 100 (75.8 to 100) |
| ST5 Day 365 | 50.0 (30.7 to 69.3) | 66.7 (39.1 to 86.2) |
| ST5 Day 545 | 22.7 (10.1 to 43.4) | 38.5 (17.7 to 64.5) |
| ST5 Month 19 | 100 (85.1 to 100) | 15.4 (4.3 to 42.2) |
| ST5 Month 24 | 95.5 (78.2 to 99.2) | 8.3 (1.5 to 35.4) |
| ST5 Month 30 | 90.9 (72.2 to 97.5) | 8.3 (1.5 to 35.4) |
| ST6 Day 29 | 4.5 (0.8 to 21.8) | 0.0 (0.0 to 22.8) |
| ST6 Day 57 | 18.2 (7.3 to 38.5) | 0.0 (0.0 to 22.8) |
| ST6 Day 85 | 68.2 (47.3 to 83.6) | 91.7 (64.6 to 98.5) |
| ST6 Day 180 | 22.7 (10.1 to 43.4) | 38.5 (17.7 to 64.5) |
| ST6 Day 208 | 95.2 (77.3 to 99.2) | 100 (75.8 to 100) |
| ST6 Day 365 | 40.9 (23.3 to 61.3) | 75.0 (46.8 to 91.1) |
| ST6 Day 545 | 13.6 (4.7 to 33.3) | 30.8 (12.7 to 57.6) |
| ST6 Month 19 | 100 (85.1 to 100) | 30.8 (12.7 to 57.6) |
| ST6 Month 24 | 95.5 (78.2 to 99.2) | 25.0 (8.9 to 53.2) |
| ST6 Month 30 | 72.7 (51.8 to 86.8) | 8.3 (1.5 to 35.4) |
SCR for IgG against each OspA serotype ST1 to ST6, determined by ELISA, at Day 29 (Month 1), 57 (Month 2), 85 (Month 3), 180 (Month 6), 208 (Month 7), 365 (Month 12), 545 (Month 18), Month 19, Month 24, and Month 30 stratified by age group: 50 - 65 years. Seroconversion for ELISA was defined as 1) for participants that are seronegative at Visit 1 (baseline): a change from seronegative at Visit 1 to seropositive at a certain time point or 2) for participants that are seropositive at Visit 1 (baseline): \>=4-fold rise in IgG antibody titer from Visit 1. SCR was reported as percentage of participants. The outcome measure was planned to be analyzed for Booster PP population from Day 29 to Day 545 of main study phase and from day of vaccination in Month 18 up to Month 30 of booster phase.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| ST1 Day 29 | 0.0 (0.0 to 20.4) | 0.0 (0.0 to 43.4) |
| ST1 Day 57 | 6.7 (1.2 to 29.8) | 0.0 (0.0 to 43.4) |
| ST1 Day 85 | 53.3 (30.1 to 75.2) | 80.0 (37.6 to 96.4) |
| ST1 Day 180 | 26.7 (10.9 to 52.0) | 40.0 (11.8 to 76.9) |
| ST1 Day 208 | 100 (78.5 to 100) | 100 (56.6 to 100) |
| ST1 Day 365 | 46.7 (24.8 to 69.9) | 20.0 (3.6 to 62.4) |
| ST1 Day 545 | 20.0 (7.0 to 45.2) | 20.0 (3.6 to 62.4) |
| ST1 Month 19 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST1 Month 24 | 86.7 (62.1 to 96.3) | 20.0 (3.6 to 62.4) |
| ST1 Month 30 | 46.7 (24.8 to 69.9) | 20.0 (3.6 to 62.4) |
| ST2 Day 29 | 6.7 (1.2 to 29.8) | 0.0 (0.0 to 43.4) |
| ST2 Day 57 | 0.0 (0.0 to 20.4) | 0.0 (0.0 to 43.4) |
| ST2 Day 85 | 93.3 (70.2 to 98.8) | 80.0 (37.6 to 96.4) |
| ST2 Day 180 | 46.7 (24.8 to 69.9) | 20.0 (3.6 to 62.4) |
| ST2 Day 208 | 92.9 (68.5 to 98.7) | 100 (56.6 to 100) |
| ST2 Day 365 | 80.0 (54.8 to 93.0) | 40.0 (11.8 to 76.9) |
| ST2 Day 545 | 40.0 (19.8 to 64.3) | 20.0 (3.6 to 62.4) |
| ST2 Month 19 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST2 Month 24 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST2 Month 30 | 86.7 (62.1 to 96.3) | 20.0 (3.6 to 62.4) |
| ST3 Day 29 | 0.0 (0.0 to 20.4) | 0.0 (0.0 to 43.4) |
| ST3 Day 57 | 0.0 (0.0 to 20.4) | 0.0 (0.0 to 43.4) |
| ST3 Day 85 | 86.7 (62.1 to 96.3) | 100 (56.6 to 100) |
| ST3 Day 180 | 46.7 (24.8 to 69.9) | 40.0 (11.8 to 76.9) |
| ST3 Day 208 | 92.9 (68.5 to 98.7) | 100 (56.6 to 100) |
| ST3 Day 365 | 66.7 (41.7 to 84.8) | 40.0 (11.8 to 76.9) |
| ST3 Day 545 | 33.3 (15.2 to 58.3) | 20.0 (3.6 to 62.4) |
| ST3 Month 19 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST3 Month 24 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST3 Month 30 | 86.7 (62.1 to 96.3) | 20.0 (3.6 to 62.4) |
| ST4 Day 29 | 0.0 (0.0 to 20.4) | 0.0 (0.0 to 43.4) |
| ST4 Day 57 | 0.0 (0.0 to 20.4) | 0.0 (0.0 to 43.4) |
| ST4 Day 85 | 73.3 (48.0 to 89.1) | 80.0 (37.6 to 96.4) |
| ST4 Day 180 | 33.3 (15.2 to 58.3) | 20.0 (3.6 to 62.4) |
| ST4 Day 208 | 92.9 (68.5 to 98.7) | 100 (56.6 to 100) |
| ST4 Day 365 | 60.0 (35.7 to 80.2) | 20.0 (3.6 to 62.4) |
| ST4 Day 545 | 26.7 (10.9 to 52.0) | 40.0 (11.8 to 76.9) |
| ST4 Month 19 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST4 Month 24 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST4 Month 30 | 80.0 (54.8 to 93.0) | 20.0 (3.6 to 62.4) |
| ST5 Day 29 | 13.3 (3.7 to 37.9) | 0.0 (0.0 to 43.4) |
| ST5 Day 57 | 13.3 (3.7 to 37.9) | 0.0 (0.0 to 43.4) |
| ST5 Day 85 | 73.3 (48.0 to 89.1) | 100 (56.6 to 100) |
| ST5 Day 180 | 20.0 (7.0 to 45.2) | 40.0 (11.8 to 76.9) |
| ST5 Day 208 | 100 (78.5 to 100) | 100 (56.6 to 100) |
| ST5 Day 365 | 46.7 (24.8 to 69.9) | 80.0 (37.6 to 96.4) |
| ST5 Day 545 | 13.3 (3.7 to 37.9) | 20.0 (3.6 to 62.4) |
| ST5 Month 19 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST5 Month 24 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST5 Month 30 | 66.7 (41.7 to 84.8) | 20.0 (3.6 to 62.4) |
| ST6 Day 29 | 6.7 (1.2 to 29.8) | 0.0 (0.0 to 43.4) |
| ST6 Day 57 | 6.7 (1.2 to 29.8) | 0.0 (0.0 to 43.4) |
| ST6 Day 85 | 73.3 (48.0 to 89.1) | 80.0 (37.6 to 96.4) |
| ST6 Day 180 | 33.3 (15.2 to 58.3) | 60.0 (23.1 to 88.2) |
| ST6 Day 208 | 100 (78.5 to 100) | 100 (56.6 to 100) |
| ST6 Day 365 | 53.3 (30.1 to 75.2) | 80.0 (37.6 to 96.4) |
| ST6 Day 545 | 20.0 (7.0 to 45.2) | 20.0 (3.6 to 62.4) |
| ST6 Month 19 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST6 Month 24 | 100 (79.6 to 100) | 20.0 (3.6 to 62.4) |
| ST6 Month 30 | 73.3 (48.0 to 89.1) | 20.0 (3.6 to 62.4) |
SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| Percentage of Participants With SAEs During the Entire Booster Phase | 7.7 (2.7 to 20.3) | 0.0 (0.0 to 16.8) |
SAE was any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| Percentage of Participants With Related SAEs During the Entire Booster Phase | 0.0 (0.0 to 9.0) | 0.0 (0.0 to 16.8) |
AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| Percentage of Participants With Adverse Event of Special Interest (AESIs) During the Entire Booster Phase | 2.6 (0.5 to 13.2) | 0.0 (0.0 to 16.8) |
AESIs were defined as serious or non-serious AEs which were of scientific and medical concern specific to the investigational product. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| Percentage of Participants With Related AESIs During the Entire Booster Phase | 0.0 (0.0 to 9.0) | 0.0 (0.0 to 16.8) |
An unsolicited AE includes any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| Percentage of Participants With Unsolicited AEs During the Booster Phase up to Month 19 | 15.4 (7.2 to 29.7) | 5.3 (0.9 to 24.6) |
An unsolicited AE included any untoward medical occurrence in a clinical investigation participant temporally associated with the use of investigational product, whether or not related to investigational product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up (more than 6 days after vaccination) for solicited symptoms. Relatedness to study vaccine was assessed by the investigator. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| Percentage of Participants With Related Unsolicited AEs During the Booster Phase up to Month 19 | 5.1 (1.4 to 16.9) | 0.0 (0.0 to 16.8) |
Solicited local AEs included pain, tenderness, induration (hardening), swelling and erythema (redness). Solicited systemic AEs included headache, myalgia (muscle pain), arthralgia (joint pain), fever (oral body temperature), flu-like symptoms, nausea, vomiting and fatigue. Two-sided 95% confidence intervals were calculated according to Altman method.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| Solicited local AEs | 89.7 (76.4 to 95.9) | 42.1 (23.1 to 63.7) |
| Solicited systemic AEs | 51.3 (36.2 to 66.1) | 31.6 (15.4 to 54.0) |
Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs during booster phase stratified by age group 18-49 years and 50-65 years were reported. SAE: any untoward medical occurrence that at any dose resulted in any of the following outcomes or deemed significant for any other reason: death; required inpatient prolonged existing hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly/birth defect. AESI: any AEs of scientific/medical concern specific to study vaccine; Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AE: any untoward medical occurrence in participant associated with use of study vaccine, whether or not related to study vaccine, reported in addition to solicited and any solicited symptom with onset outside specified period of follow-up.
| Percentage of Participants | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|
| SAE: 18-49 Years | 4.5 (0.8 to 21.8) | 0.0 (0.0 to 21.5) |
| SAE: 50-65 Years | 11.8 (3.3 to 34.3) | 0.0 (0.0 to 43.4) |
| AESI: 18-49 Years | 0.0 (0.0 to 14.9) | 0.0 (0.0 to 21.5) |
| AESI: 50-65 Years | 5.9 (1.0 to 27.0) | 0.0 (0.0 to 43.4) |
| Solicited AE: 18-49 Years | 86.4 (66.7 to 95.3) | 42.9 (21.4 to 67.4) |
| Solicited AE: 50-65 Years | 94.1 (73.0 to 99.0) | 80.0 (37.6 to 96.4) |
| Unsolicited AE: 18-49 Years | 9.1 (2.5 to 27.8) | 0.0 (0.0 to 21.5) |
| Unsolicited AE: 50-65 Years | 23.5 (9.6 to 47.3) | 20.0 (3.6 to 62.4) |
Collected over Solicited AEs (systematic assessment [SA]): up to 7 days after each vaccination; Main study phase: unsolicited AEs (non-SA) including SAEs: up to Day 545; Booster phase: unsolicited AEs (non-SA): From day of vaccination in booster phase (Month 18) up to Month 19 (1 month), SAEs: From day of vaccination in booster phase (Month 18) up to Month 30 (12 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study Phase: VLA15 With Alum Lower Dose | 0/97 (0%) | 4/97 (4.1%) | 94/97 (96.9%) |
| Main Study Phase: VLA15 With Alum Higher Dose | 0/98 (0%) | 4/98 (4.1%) | 97/98 (99%) |
| Main Study Phase: Placebo | 0/51 (0%) | 2/51 (3.9%) | 40/51 (78.4%) |
| Booster Phase: VLA15 With Alum Higher Dose | 0/39 (0%) | 3/39 (7.7%) | 35/39 (89.7%) |
| Booster Phase: Placebo | 0/19 (0%) | 0/19 (0%) | 11/19 (57.9%) |
| Event | Main Study Phase: VLA15 With Alum Lower Dose | Main Study Phase: VLA15 With Alum Higher Dose | Main Study Phase: Placebo | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/97 | 1/98 | 0/51 | 1/39 | 0/19 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 0/97 | 0/98 | 0/51 | 1/39 | 0/19 |
| Small intestinal obstructionGastrointestinal disorders | 0/97 | 0/98 | 0/51 | 1/39 | 0/19 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/97 | 0/98 | 1/51 | 0/39 | 0/19 |
| Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/97 | 0/98 | 1/51 | 0/39 | 0/19 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/97 | 0/98 | 0/51 | 0/39 | 0/19 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/97 | 0/98 | 0/51 | 0/39 | 0/19 |
| VertigoEar and labyrinth disorders | 1/97 | 0/98 | 0/51 | 0/39 | 0/19 |
| Obstructive pancreatitisGastrointestinal disorders | 1/97 | 0/98 | 0/51 | 0/39 | 0/19 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/97 | 1/98 | 0/51 | 0/39 | 0/19 |
| Event | Main Study Phase: VLA15 With Alum Lower Dose | Main Study Phase: VLA15 With Alum Higher Dose | Main Study Phase: Placebo | Booster Phase: VLA15 With Alum Higher Dose | Booster Phase: Placebo |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 93/97 | 95/98 | 16/51 | 35/39 | 5/19 |
| MyalgiaMusculoskeletal and connective tissue disorders | 54/97 | 55/98 | 11/51 | 11/39 | 1/19 |
| HeadacheNervous system disorders | 45/97 | 45/98 | 18/51 | 8/39 | 4/19 |
| Injection site erythemaGeneral disorders | 28/97 | 41/98 | 8/51 | 7/39 | 3/19 |
| FatigueGeneral disorders | 31/97 | 33/98 | 13/51 | 8/39 | 2/19 |
| Injection site swellingGeneral disorders | 24/97 | 32/98 | 1/51 | 3/39 | 1/19 |
| Injection site indurationGeneral disorders | 27/97 | 29/98 | 1/51 | 2/39 | 0/19 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 24/97 | 23/98 | 8/51 | 4/39 | 1/19 |
| Influenza like illnessGeneral disorders | 18/97 | 9/98 | 10/51 | 1/39 | 0/19 |
| NauseaGastrointestinal disorders | 18/97 | 17/98 | 6/51 | 3/39 | 0/19 |
Safety population included all participants who entered into the study and received at least 1 dose of vaccination.
| Age, Continuous(years) | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo | Total |
|---|---|---|---|---|
| Main Study Phase | 43.5 ± 12.61 | 43.0 ± 12.76 | 45.0 ± 12.79 | 43.6 ± 12.68 |
| Booster Phase: VLA15 with Alum higher dose | — | 46.5 ± 13.15 | — | 46.5 ± 13.15 |
| Booster Phase: Placebo | — | 38.8 ± 13.50 | — | 38.8 ± 13.50 |
| Sex: Female, Male(Participants) | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo | Total |
|---|---|---|---|---|
| Main Study Phase — Female | 49 | 50 | 34 | 133 |
| Main Study Phase — Male | 48 | 48 | 17 | 113 |
| Booster Phase: VLA15 with Alum higher dose — Female | 0 | 23 | 0 | 23 |
| Booster Phase: VLA15 with Alum higher dose — Male | 0 | 16 | 0 | 16 |
| Booster Phase: Placebo — Female | 0 | 7 | 0 | 7 |
| Booster Phase: Placebo — Male | 0 | 12 | 0 | 12 |
| Race (NIH/OMB)(Participants) | VLA15 With Alum Lower Dose | VLA15 With Alum Higher Dose | Placebo | Total |
|---|---|---|---|---|
| Main Study Phase — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Main Study Phase — Asian | 0 | 1 | 0 | 1 |
| Main Study Phase — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Main Study Phase — Black or African American | 4 | 4 | 0 | 8 |
| Main Study Phase — White | 91 | 93 | 51 | 235 |
| Main Study Phase — More than one race | 0 | 0 | 0 | 0 |
| Main Study Phase — Unknown or Not Reported | 2 | 0 | 0 | 2 |
| Booster Phase: VLA15 with Alum higher dose — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Booster Phase: VLA15 with Alum higher dose — Asian | 0 | 1 | 0 | 1 |
| Booster Phase: VLA15 with Alum higher dose — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Booster Phase: VLA15 with Alum higher dose — Black or African American | 0 | 4 | 0 | 4 |
| Booster Phase: VLA15 with Alum higher dose — White | 0 | 34 | 0 | 34 |
| Booster Phase: VLA15 with Alum higher dose — More than one race | 0 | 0 | 0 | 0 |
| Booster Phase: VLA15 with Alum higher dose — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Booster Phase: Placebo — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Booster Phase: Placebo — Asian | 0 | 0 | 0 | 0 |
| Booster Phase: Placebo — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Booster Phase: Placebo — Black or African American | 0 | 0 | 0 | 0 |
| Booster Phase: Placebo — White | 0 | 19 | 0 | 19 |
| Booster Phase: Placebo — More than one race | 0 | 0 | 0 | 0 |
| Booster Phase: Placebo — Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2019 to primary completion in Apr 2020, 9 months.
Results were first posted in Jul 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VLA15